Drug, bio-affecting and body treating compositions inventions 03/08

20080070827 - Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg coa reductase, and increase ldl receptor and sp1 expression in a mammal: Controlled studies demonstrate that methods using soy related peptides inhibit H3 acetylation, reduce expression of HMG CoA reductase and increase LDL receptor and Sp1 expression in mammals. The present disclosure is generally directed to using lunasin peptides and/or lunasin peptide derivatives to 1) inhibit H3 acetylation, 2) reduce expression of... Agent: Kathryn P.wilke C/o Gaw Van Male

20080070837 - Bmp-4 variants with improved properties: The invention relates to variants of BMP-4 with improved properties and methods for their use.... Agent: Morgan, Lewis & Bockius, LLP

20080070839 - Composition and method for treating cancer: The present invention provides a compound for treating cancer including an isolated form of dibenzyl trisulfide (DTS) provided in an effective amount to act as an agent against human diseases, including various forms of cancer. The present invention also provides a compound for treating cancer including DTS isolated from Petiveria... Agent: Triangle Patents, P.l.l.c.

20080070836 - Emt-inducing agents: The mechanism of STAT3, which is considered to play a crucial role in EMT, was elucidated using zebrafish embryos. Unexpectedly, a STAT3 target gene turned out to be zinc transporter LIV1. The present inventors studied the relationship between STAT3 and LIV1 in EMT, and further studied their relationship with zinc... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080070835 - Hla-dr-binding antigen peptide derived from wt1: The present invention provides a WT1-derived HLA-DRB1*0405-binding antigen peptide, a polynucleotide encoding said peptide, a helper T cell inducer comprising said peptide or polynucleotide, and the like. It is related to a partial peptide consisting of 10-25 contiguous amino acids in the amino acid sequence of human WT1 shown in... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080070845 - Method and formulations to concurrently reduce fracture risk and insure appropriate fat-soluble vitamin supplementation when using orlistat, an oral lipase inhibitor: Orlistat is an oral lipase inhibitor that blocks the absorption of ingested fats from the small intestines, to enable proven weight loss. Fat-soluble vitamin deficiencies can be a consequence of orlistat use, especially if used for a long time without medical supervision. The present invention comprises a fat-soluble-only vitamin complex,... Agent: Donald N. Halgren

20080070850 - Gallotannins and elligitannins as regulators of cytokine release: A means and method for increasing or inhibiting the secretion of cytokines using gallotannins and ellagitannins is described. The preferred cytokine release inhibiting compounds are dimeric gallotannins having a linker molecule that misaligns the carbohydrate cores of the compounds. The preferred cytokine release promoting gallotannins and ellagitannins include a diaryl... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pennsylvania State University

20080070852 - Method for the extraction of pharmaceutically active products from spermatophyte plants, products thus obtained and their use in the medical field, in particular as substances with immunomodulating activity: The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.... Agent: Novartis Corporate Intellectual Property

20080070854 - Conserved hbv and hcv sequences useful for gene silencing: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080070853 - Peptides selectively lethal to malignant and transformed mammalian cells: The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein, which peptides are lethal to malignant or transformed cells when fused to a membrane-penetrating leader sequence. The subject peptides are thus useful in treating neoplastic disease in an animal, preferably... Agent: Dilworth & Barrese, LLP

20080070855 - Treatment with anti-vegf agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes: Provided are methods for preventing post-operative neovascularization and/or inflammation in ophthalmic tissue of a patient undergoing ophthalmic surgery by administering a therapeutically effective amount of an anti-VEGF compound to the ophthalmic tissue of a patient where the anti-VEGF compound is administered to the patient prior to the time the ophthalmic... Agent: Kramer & Amado, P.C.

20080070863 - Combination of active substances with insecticidal properties: The invention relates to novel insecticidal active compound combinations consisting, firstly, of anthranilamides and, secondly, of further insecticidally active compounds from the group of the pyrethroids, which combinations are highly suitable for controlling animal pests, such as insects.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080070864 - Quinazolinone modulators of nuclear receptors: Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080070865 - Triphenylphosphine oxide derivatives and uses thereof: m

20080070826 - Cholesterol-reducing diet: A method of treating cholesterol imbalance, high LDLs, and other metabolic syndrome problems and symptoms of osteoarthritis. The regimen preferred embodiment includes lipids as 60% or more of daily caloric content, protein up to 10%-15% of daily caloric content; and carbohydrates up to 25% or less of daily caloric content,... Agent: Michael M. De Angeli, P.C. Attorney At Law

20080070828 - Ace-inhibitory whey hydrolysates: The invention relates to compounds with an antihypertensive effect. More in particular, the invention relates to releasing ACE (angiotensin I-converting enzyme)-inhibitory peptides from whey proteins. The invention provides a method for enzymatically producing a protein hydrolysate with angiotensin-converting enzyme (ACE)-inhibitory activity, characterized by treatment of a beta-lactoglobulin (BLG)-containing substrate with... Agent: Norris, Mclaughlin & Marcus, P.A.

20080070829 - Family of pesticidal proteins and methods for their use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for pesticidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise... Agent: Alston & Bird LLP

20080070830 - Homing of cells to myocardium: The invention provides compositions such modified cells and methods of promoting healing of an injured tissue by enhancing the migration of primary or immortalized progenitor or stem cells and enhancing their engraftment into a target tissue site in mammalian recipient such as a human subject. For example, the cells are... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080070831 - Vascular endothelial growth factor d(vegf-d) antibodies and vectors, and methods of uses: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it,... Agent: Marshall, Gerstein & Borun LLP

20080070833 - Lactoferrin in the reduction of pain: The present invention relates to methods of using lactoferrin (LF) to reduce pain in conditions associated with severe or intractable pain by administering a composition of lactoferrin either alone or in combination with other therapy for pain.... Agent: Fulbright & Jaworski, LLP

20080070832 - Method for purifying fsh: The invention relates to a method for purifying recombinant human FSH or an FSH variant starting from crude FSH, comprising the following steps: 1. dye-affinity chromatography; 2. hydrophobic interaction chromatography; and 3. reverse phase chromatography.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080070834 - Cyclosporin compositions: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.... Agent: Allergan, Inc.

20080070838 - Growth factor treatment for asthma: The present invention relates to use of epidermal growth factor (EGF) analogues to treat, or protect from, bronchial epithelium damage in asthma patients. Suitable such analogues target the EGF receptor and exhibit ability to promote in asthma patients preferential proliferation of bronchial epithelial cells compared to airway fibroblasts.... Agent: Morrison & Foerster LLP

20080070842 - Recombinant bone morphogenetic protein heterodimers, compositions and methods of use: The present invention relates to methods for producing recombinant heterodimeric BMP proteins useful in the field of treating bone defects, healing bone injury and in wound healing in general. The invention also relates to the recombinant heterodimers and compositions containing them.... Agent: Wyeth/finnegan Henderson, LLP

20080070840 - Thrombopoietic compounds: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.... Agent: Amgen Inc.

20080070841 - Use of serp-1 as an antiplatelet agent: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided.... Agent: Peter I. Bernstein Scully, Scott, Murphy & Presser

20080070843 - Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics: The present invention provides small molecules having high affinity to the ATP binding site of protein kinases, which are conjugated to apeptide or peptidomimetic moiety which mimics the substrate of PKB. The chimeric compounds according to the present invention preferably serve as PKB inhibitors with improved activity and selectivity. Novel... Agent: Cooper & Dunham, LLP

20080070844 - Method for treating wounds to promote healing: A method of treating a mammal to promote wound healing in the mammal in need thereof, comprising orally administering to the mammal an effective amount of a palatable, concentrated protein composition comprising an effective amount of hydrolysed gelatin and tryptophan, and an ingestible carrier, the composition comprising the essential amino... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080070846 - Treating acute exacerbations of asthma using a ketolide: Provided herein is a method of treating a patient suffering from, or subject to, acute asthma exacerbations comprising administering to the patient a pharmaceutically effective amount of a ketolide.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080070847 - Anti-cancer combinations: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid... Agent: Jaeckle Fleischmann & Mugel, LLP

20080070848 - Anti-cancer combinations: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid... Agent: Jaeckle Fleischmann & Mugel, LLP

20080070849 - Anti-cancer combinations: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid... Agent: Jaeckle Fleischmann & Mugel, LLP

20080070851 - Method for the extraction of pharmaceutically active products from spermatophyte plants, products thus obtained and their use in the medical field, in particular as substances with immunomodulating activity: A method is described for the extraction of products having a pharmacological activity, in particular an immunomodulating activity, from spermatophyte plants. Said products, which are to be used in the pharmaceutical fields, consist of complex mixtures of compounds characterized by one or more stilbene groups, variously hydroxylated and/or glucosidated, and... Agent: Greenberg Traurig, LLP

20080070858 - Materials and methods for treatment of allergic diseases: The present invention pertains to a method for treatment of allergic diseases by administering a natriuretic hormone peptide (NHP), or a nucleic acid sequence encoding NHP, to a patient in need thereof. In another aspect, the present invention concerns an expression vector comprising a nucleic acid sequence encoding NHP. In... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080070856 - Medicament to treat a fibrotic disease: The invention relates to a drug for treating a fibrotic disease, said drug containing a double straded ribonucleic acid (dsRNA) suitable for inhibiting, through RNA interference, the expression of a gene involved in the formation of extracellular matrix.... Agent: Swanson & Bratschun, L.L.C.

20080070857 - Pharmaceutical agents for preventing metastasis of cancer: This invention relates to a pharmaceutical agent for preventing metastasis of cancer, which comprises a substance that inhibits expression of macrophage migration inhibitory factor (MIF). Such substance includes siRNA of MIF.... Agent: Morgan Lewis & Bockius LLP

20080070860 - Adenosine analogs useful as anti-bacterial and anti protozoan agents: The present invention is directed to purine nucleoside analogs of the general Formula (I), or tautomers thereof, physiologically acceptable salts, solvents and physiologically functional derivatives thereof, and pharmaceutical compositions comprising such compounds, salts and derivatives, which are useful as anti-bacterial and anti-protozoan agents. The invention is also directed to methods... Agent: Bennett Jones C/o Ms Roseann Caldwell

20080070859 - Compounds resistant to metabolic deactivation and methods of use: Therapeutic compounds having increased resistance to deamination and inactivation by metabolic enzymes are provided. The compounds include nucleotide analogs and nucleotide analogs, derivatized with aminal and/or thioaminal groups to prevent deamination of free amine. The compounds can be used in a variety of treatments, including treatment of neoplastic disorders, infections... Agent: Lahive & Cockfield, LLP

20080070861 - Modified fluorinated nucleoside analogues: The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.... Agent: Duane Morris LLPIPDepartment

20080070862 - Methods using glycosaminoglycans for the treatment of nephropathy: The present invention relates to a method for the treatment of HIV-associated nephropathy by administration of glycosaminoglycans, and in particular, by the administration of sulodexide.... Agent: Jones Day

20080070866 - Chemical compounds: The invention provides compounds of formula I and formula II, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080070867 - 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases: Compounds and compositions are provided for modulating the activity of protein tyrosine phosphatases. The compounds for use in the compositions and methods provided herein have formulae (I) Protein tyrosine phosaphatase, including PTB-IB, mediated diseases and disorders include diabetes including Type 1 and Type 2 diabetes (and associated complications such as... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080070868 - Novel thiazole inhibitors of fructose 1,6-bisphosphatase: Compounds of Formula I, their prodrugs and salts, their preparation and their uses are described.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080070869 - Malonyl-coa decarboxylase inhibitors useful as metabolic modulators: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to... Agent: Fish & Richardson P.C.

20080070870 - Use of omega-3 rich phospholipids in the area of cognitive function: The invention disclosed describes the of omega-3 rich phospholipids for treating symptoms of cognitive dysfunction in children, children with developmental cognitive disorder, children with autism, elderly subjects with Alzheimer's disease and elderly subjects with age associated cognitive decline.... Agent: Casimir Jones, S.c.

20080070871 - N-phenylphosphoric acid triamides, method for the production thereof and their use as agents for regulating or inhibiting enzymatic urea hydrolysis: The invention relates to N-phenylphosphonic acid triamides of general formula (I), to a method for the production thereof and to their use as agents for regulating or inhibiting enzymatic urea hydrolysis. In formula (I), X represents oxygen or sulfur; R1, R2, R3, R4, R5, independent of one another, represent hydrogen... Agent: Nixon & Vanderhye, PC

20080070872 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Knobbe Martens Olson & Bear LLP

20080070873 - Methods of increasing oral bioavailability of tetracyclines: Methods for increasing the oral bioavailability of tetracycline compounds are described.... Agent: Lahive & Cockfield, LLP

20080070874 - Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes: Acne-affected skin has been found to be accompanied by the presence of matrix-degrading enzymes such as MMPs and neutrophil elastase, induction of neutrophils, and a reduction in procollagen biosynthesis. This invention treats scarring and inflammation accompanying acne by administering, topically or systemically, at least one of (i) an inhibitor of... Agent: Bradley N. Ruben, PC

20080070875 - Acne treatment compositions and methods of use: The present invention relates to a composition for treating acne comprising an antimicrobial/anti-inflammatory polyphenolic molecule(s) including quercetin and rosmarinic acid in combination with salicyclic acid and/or salicylate salts in a topical and/or cosmetic delivery vehicle. The invention further relates to a method for treating acne by topically administering one of... Agent: Duane Morris LLP Patent Department

20080070878 - Foaming composition for washing and treating hair and/or scalp based on an active principle: The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterised in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating agent.... Agent: Nixon & Vanderhye, PC

20080070876 - Gaba-steroid antagonists and their use for the treatment of cns disorders: Compounds exhibiting 3alpha-hydroxy-5alpha/beta-steroid blocking action with no or only low antagonism against the gamma-aminobutyric acid (A) receptor (GABA-A), and compounds exhibiting partial antagonism against said receptor are presented. Methods for the prevention, treatment and/or alleviation of various CNS-disorders are suggested, as well as pharmaceutical compositions for such use.... Agent: Morrison & Foerster LLP

20080070877 - Process of epilobium species for treatment of hormone balance in warm blooded animals, and method of manufacturing: The present invention includes the selection of a particular species of Epilobium, and the production of an efficacious Epilobium extract. The method of extraction utilized in the present invention includes the selection and separation of parts of Epilobium Parviflorum plant to be used, excluding the use of solid stems and... Agent: Gary L. Eastman

20080070879 - 7-keto dhea for psychiatric use: The present invention comprises novel methods for the use of compositions comprising 7-keto DHEA for treating psychiatric conditions. These methods include administering an effective amount of a composition comprising 7-keto DHEA in an acceptable carrier, alone or in combination with other psychiatric drugs, such as analgesic agents, anticonvulsants, anti-anxiety agents,... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080070880 - Specific glucocorticosteroid compound having anti-inflammatory activity: e

20080070881 - Prostate cancer treatment: The instant invention provides potent antiandrogen compounds, such as 3β-acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1,5-diene-17-ethylene ketal, and methods for their use in the prevention and treatment of biological conditions mediated by androgen receptors. Thus, for example, compounds of the invention are useful in the prevention and treatment of prostrate cancer. Furthermore, it... Agent: Hollis-eden Pharmaceuticals, Inc.

20080070882 - Vaginal cream compositions, kits thereof and methods of using thereof: The present invention is directed to pharmaceutical vaginal cream compositions comprising a conjugated estrogen and a stabilizer. The present invention is also directed to a method of treating a menopausal condition in a female in need thereof, said method comprising vaginally administering a pharmaceutical vaginal cream composition comprising a conjugated... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080070883 - Use of lxr modulators for the prevention and treatment of skin aging: Disclosed herein are compounds for preventing or treating skin aging through the use of LXR modulators and methods of use thereof.... Agent: Potter Anderson & Corroon LLP/wyeth

20080070884 - Cyclic nonapeptide amides: The invention relates to cyclic nonapeptide amides and to methods for their preparation and to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially bacterial infectious diseases.... Agent: Morrison & Foerster LLP

20080070885 - Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof: The present invention relates to macro-cyclic compounds of formula (I), wherein R1, is (C1-8)alkyl, (C1-4)alkoxy(C1-4)alkyl, hydroxy(C1-6)alkyl, (C1-4)alkylthio(C1-4)alkyl, (C1-6)alkenyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, piperidinyl or pyrrolidinyl, R2 and R4, independently, are hydrogen or optionally substituted (C1-8)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, aryl, aryl(C1-4)alkyl, heteroaryl or heteroaryl(C1-4)alkyl, or R2 and R4, together with the nitrogen to which... Agent: Novartis Corporate Intellectual Property

20080070886 - Anti-cancer combinations: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid... Agent: Jaeckle Fleischmann & Mugel, LLP

20080070888 - Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism: wherein Z1 is —CH2— or —C(O)—, R4 and R5 are carbon chains (and optionally, together can form a C2 bridge), u and v are independently an integer of 0-3 such that there sum is from 3 to 5, and R2 is heteroaryl, and R1 and R3 are as defined herein.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080070889 - Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism: wherein Z1 is —CH2— or —C(O)—, R4 and R5 are carbon chains (and optionally, together can form a C2 bridge), u and v are independently an integer of 0-3 such that there sum is from 3 to 5, and R2 is heteroaryl, and R1 and R3 are as defined herein.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080070890 - Spirocyclic azetidinone compounds and methods of use thereof: The present invention relates to Spirocyclic Azetidinone Compounds, compositions comprising a Spirocyclic Azetidinone Compound and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of a Spirocyclic Azetidinone Compound.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080070891 - (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane: The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.... Agent: Robert Deberardine Abbott Laboratories

20080070892 - Treating pain, diabetes, and disorders of lipid metabolism: e

20080070893 - Protein kinase inhibitors: Pyrimidine- and triazine-based chemical compounds that are useful, for example, as protein kinase inhibitors for treating cancer, neurological disorders, autoimmune disorders, and other diseases, and methods of using such compounds... Agent: Woodcock Washburn LLP

20080070887 - Diaryl ether derivatives and uses thereof: r

20080070895 - Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase:

20080070894 - Novel substituted imidazole derivative:

20080070896 - Pyrimidine derivative condensed with a non-aromatic ring: There are provided new pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety, and the like or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080070897 - Spontaneously dispersible n-benzoyl staurosporine compositions: Spontaneously dispersible N-benzoyl-staurosporine compositions are discussed for oral administration having high bioavailability levels and reduced variability of bioavailability levels of N-benzoyl-staurosporine, as well as their preparation and use in medical treatment.... Agent: Novartis Corporate Intellectual Property

20080070898 - Piperidine derivative or pharmaceutically acceptable salt thereof: The piperidine derivative of the present invention in which the 4-position of the piperidine ring is bonded, via vinylene, to a mono-substituted (—R1) or unsubstituted benzene ring and the 1-position of the piperidine ring has an acyl group [—C(═O)—R4], or a pharmaceutically acceptable salt thereof has an excellent sodium channel... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080070899 - Cgrp receptor antagonists: The present invention is directed to compounds of Formula I: Formula I: I and Formula II: (where variables R1, R2, R3, R4, A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of... Agent: Merck And Co., Inc

20080070901 - Cholineterase inhibitors for treating inflammation: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080070900 - Method of treating organophosphorous poisoning: A method of treating organophosphorous (OP) poisoning comprising administering to a mammal at risk for OP poisoning an OP poisoning-inhibiting amount of galantamine.... Agent: Larcher & Chao LLP

20080070902 - Cinnamide compound: (wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted;... Agent: Birch Stewart Kolasch & Birch

20080070903 - New pyrimidine derivatives and new pyridine derivatives: Achiral pyrimidine derivatives and pyridine derivatives of the following formulae or analogs thereof have selective N-type calcium channel antagonistic activity and showed analgesic action when they were taken orally. They are useful as therapeutic agents for pains and various diseases associated with the N-type calcium channels.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080070904 - Pharmaceutical compositions of benzodiazepines and method of use thereof: The present invention includes benzodiazepine compositions formulated for intranasal administration, comprising a binary solvent system comprising a first solvent in which the benzodiazepine is soluble, the first solvent capable of penetrating nasal mucosal tissue, and a second solvent in which the benzodiazepine in less soluble. The compositions of the present... Agent: Jazz Pharmaceuticals

20080070905 - Small molecule inhibitors of kynurenine-3-monooxygenase: The present invention relates to compounds of formula Ia or Ib below and their tautomers and/or pharmaceutically acceptable salts and compositions and methods of uses thereof.... Agent: Foley & Lardner LLP

20080070906 - Quinolinone derivatives: Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according... Agent: Foley & Lardner LLP

20080070908 - Compositions including antibiotics and methods for using same: Compositions including a quinolone component, such as ofloxacin, having fungistatic activity in the compositions, present in an amount effective as an antibiotic when the composition is placed in a mammalian eye, a NSAID component present in an amount to reduce inflammation or pain when the composition is placed in the... Agent: Stout, Uxa, Buyan & Mullins LLP

20080070907 - Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods: Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines, and imidazo[4,5-c]pyridines) with a —CH(—R2)— group in the fused ring at the 2-position of the imidazo ring and a —CH(—R1)— group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of... Agent: Wolf Greenfield & Sacks, P.C.

20080070909 - Enantiomerically pure beta agonists, manufacturing and use thereof: b

20080070910 - Therapeutic compounds and methods:

20080070911 - Ion channel modulating compounds and uses thereof: Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local... Agent: Seed Intellectual Property Law Group PLLC

20080070912 - Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use: The present invention is directed to substituted pyrazolo[1,5-α]pyridines and related methods for their synthesis and use.... Agent: Perkins Coie LLP

20080070913 - Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors: X, m, n, q, R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, Q, Z, Z′, Z′″, Z″ and J are defined hereinbefore in the specification, which are useful in the treatment of cancer, stroke, myocardial infarction, neuropathic pain, osteoporosis, polycystic kidney disease, autoimmune disease, rheumatoid arthritis, and transplant... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick&lockhart Nicholson Graham)

20080070914 - 5-membered annelated heterocyclic pyrimidines as kinase inhibitors:

20080070915 - Quinazoline derivatives as parp inhibitors: The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compnounds of formula (I) wherein R1, R2, R3, L, X, Y and Z have defined meanings.... Agent: Philip S. Johnson Johnson & Johnson

20080070916 - Dihydropyrancarboxamides and uses thereof: and collections of these compounds, and provides methods for the synthesis of these compounds; wherein R1-R6 are as defined herein. Additionally, the present invention provides pharmaceutical compositions and methods for treating disorders such as proliferative diseases, and cancer, to name a few.... Agent: Choate, Hall & Stewart/harvard University

20080070917 - Methods for administering levosimendan: The invention relates to a method of administering an inotropic agent (such as, but not limited to, a levosimendan compound) or a pharmaceutically acceptable salt thereof in the treatment of cardiovascular disorders.... Agent: Dykema Gossett PLLC

20080070918 - Dihydropyridazine, tetrahydropyridine, chromanone, and dihydronaphthalenone derivatives: wherein A, Q1, Q2, Q3, R3, and R4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080070919 - Bridged aryl piperazines derivatives useful for the treatment of cns, gi-urinary and reproductive disorders: The present invention is directed to bridged aryl piperazine derivatives, pharmaceutical compositions containing them and their use in the treatment of depression and related disorders. The compounds of the present invention are serotonin transport inhibitors and/or modulators of 5HT1A.... Agent: Philip S. Johnson Johnson & Johnson

20080070920 - Novel hiv reverse transcriptase inhibitors: e

20080070921 - Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents: wherein the groups —C(R8)(CH2)vCH(R9)(CH2)y-Q and —C(R8)(CH2)vCH(R9)(CH2)y-J are the same, and R1a, R1b, R2a, R2b, R8, R9, J, Q, W, X, L2, v and y have meanings given in the description. Thus use of such compounds in the treatment of a condition responsive to changes in melanocortin receptor function in a... Agent: Morgan Lewis & Bockius LLP

20080070922 - Combination of organic compounds: The present invention relates to a combination, comprising; i) DPP IV inhibitor or a pharmaceutically acceptable salt thereof, and ii) at least one PDGF receptor tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof. The present invention furthermore relates to the use of such a combination for the prevention, delay... Agent: Novartis Corporate Intellectual Property

20080070923 - Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists: The invention provides novel benzoimidazolone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20080070924 - Novel formulations for opioid-based treatments of pain comprising 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives: e

20080070925 - Serotonergic agents for treating sexual dysfunction: Methods and compositions are provided for treating sexual dysfunction, e.g., sexual dysfunction associated with drug treatment, using 5-HT1A receptor antagonists.... Agent: Wilmerhale/wyeth

20080070926 - Therapeutic combinations of manidi pine and a statin: A medicament comprising (±)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester (manidipine) or a physiologically acceptable salt and a statin or a physiologically acceptable salt.... Agent: Ladas & Parry

20080070927 - Substituted heterocyclic compounds: Disclosed are novel piperazine and piperazine derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, diabetes, intermitten claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction.... Agent: Michael J. Beck Cv Therapeutics, Inc.

20080070928 - Novel 2-heteroaryl-substituted benzimidazole derivative: (in the formula, X represents a carbon atom or a nitrogen atom); R1 represents an aryl, etc.; R2 represents a hydroxy, etc.; R3 represents a —C1-6 alkyl, etc.; R4 represents a —C1-6 alkyl, etc.; X5 represents —O—, etc.; a indicates an integer of 1, 2 or 3; q indicates an... Agent: Merck And Co., Inc

20080070930 - Pyrimidine and pyrazine derivatives: wherein R0, R3, R7, n, Q1, Q2, Y, and X1-X3 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080070929 - Thiazoline and oxazoline derivatives and their methods of use: The invention relates to a series of thiazoline and oxazoline derivatives, compositions thereof, and methods of treating conditions and disorders using such compounds.... Agent: Robert Deberardine Abbott Laboratories

20080070931 - 5-phenyl-nicotinamide derivatives: e

20080070932 - 5-phenyl-nicotinamide derivatives: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagofiists. thereof for preventing and/or treating numerous diseases, including C) Parkinson's disease. In one embodiment, the invention features a compound of formual (I).... Agent: Fish & Richardson PC

20080070933 - Purine, pyrimidine, and azaindole derivatives: wherein A, R7, X1, X2, X3, Y, and n are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080070934 - Kw-3902 conjugates that do not cross the blood-brain barrier: The present invention relates to certain compounds and to methods for the preparation of certain compounds that can be used in the fields of chemistry and medicine. Specifically, described herein are methods for the preparation of various compounds and intermediates, and the compounds and intermediates themselves. More specifically, described herein... Agent: Knobbe Martens Olson & Bear LLP

20080070935 - Isoquinoline, quinazoline and phthalazine derivatives: wherein R0, R5, R6, R7, n, Q1-Q5, Y, and X1-X3 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080070936 - Compounds specific to adenosine a1 receptors and uses thereof: This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.... Agent: John P. White, Esq. Cooper & Dunham LLP

20080070938 - Medicinal composition for mitigating blood lipid or lowering blood homocysteine: A method of mitigating blood lipid levels or reducing high blood homocysteine levels administering in amounts effective for mitigating blood lipid levels or reducing high blood homocysteine levels, an HMG-CoA reductase inhibitor and a pyridoxine derivative. The pyridoxine derivative is one or more of pyridoxine, pyridoxal, pyridoxamine, and their pharmacologically... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080070937 - Small molecule inhibitors of kynurenine-3-monooxygenase: The present invention relates to compounds of Formula I below and their tautomers or pharmaceutically acceptable salts, compositions and methods of uses thereof.... Agent: Foley & Lardner LLP

20080070939 - Local anesthetic compositions containing dextrorotatory morphinan derivatives or pharmaceutically acceptable salts thereof: e

20080070940 - 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same:

20080070941 - Derivatives of n-heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics:

20080070942 - Prazole derivatives and salts thereof and use of same: The present invention relates to derivatives of compounds (formula (I) or (II)) and their salts, wherein R1 represents lower alkyl or the lower alkyl substituted by halogen atoms, R2 represents straight-chain or branched-chain alkyl containing 1-4 carbon atoms and R3 represents hydrogen atom or alkali metals such as lithium, sodium,... Agent: Workman Nydegger

20080070943 - Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20080070944 - Novel methods using aminobenzoic acid compounds: The invention provides safe and effective methods for treating and/or preventing gastrointestinal disorders, psychiatric disorders, learning disabilities, Tourette's syndrome, obesity, epilepsy, post-menopausal syndrome, pre-menstrual syndrome, asthma, laryngitis and/or migraines by administering to a patient in need thereof at least one aminobenzoic acid compound. The aminobenzoic acid compound can optionally be... Agent: Venable LLP

20080070945 - 4-(2-methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2b agonist and methods of using the same: wherein the * indicates an asymmetric carbon, is specific to alpha2B adrenergic receptors in preference over alpha2A and alpha2C adrenergic receptors, and as such has no or only minimal cardivascular and/or sedatory activity. The compound is useful as medicament in mammals, including humans, for treatment of diseases and or alleviations... Agent: Allergan, Inc.

20080070946 - Hydroxymethylbenzothiazoles amides: The present invention relates to new compounds, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080070947 - Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis: Medicaments comprising compounds of this type are of use for preventing or treating various disorders, such as, respiratory disorders and snoring, acute and chronic disorders, disorders induced by ischemic and/or reperfusion events and by proliferative or fibrotic events, disorders of the central nervous system and lipid metabolism, diabetes, blood coagulation... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080070948 - Benzimidazolidinone derivatives as muscarinic agents: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.... Agent: Knobbe Martens Olson & Bear LLP

20080070949 - Polymorphs of rimonabant: Crystalline form C of rimonabant and amorphous rimonabant, processes for their preparation and pharmaceutical compositions thereof.... Agent: Conley Rose, P.C.

20080070950 - Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2- methylpropionic acid and its pharmaceutical compositions: The present invention provides an amorphous form of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid. This invention also provides processes for preparing the amorphous form and pharmaceutical compositions including the amorphous form.... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20080070951 - Non-nucleotide reverse transcriptase inhibitors: Compounds of the formula Z: where; A is CH or N; R1 is a substituent to a carbon atom in the ring containing A selected from —S(═O)pRa, where Ra is —C1-C4 alkyl, —ORx, —NRxRx, —NHNRxRx, —NHNHC(═O)ORx, —NRxOH; —C(═O)—Rb, where Rb is —CT-C4-alkyl, ORx, —NRxRx, —NHNRxRx, —NHC1-C3-alkyl-C(═O)Orx —NRxRc, where Rc is... Agent: Birch Stewart Kolasch & Birch

20080070952 - Inhibition or treatment of dyskinesia: Prevention or treatment of dyskinesia induced by L-dopa or dopamine agonist can be effected by use of a selective inhibitor of neuronal nitric oxide synthase.... Agent: Banner & Witcoff, Ltd.

20080070953 - Inhibitors of interleukin-1 beta converting enzyme: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080070954 - Acylurea connected and sulfonylurea connected hydroxamates: The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea/sulfonylurea containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or... Agent: Connolly Bove Lodge & Hutz LLP

20080070956 - Tricyclic aromatic and bis-phenyl sulfinyl derivatives: e

20080070957 - Novel biaromatic compounds which activate ppary type receptors and cosmetic/pharmaceutical compositions comprised thereof:

20080070958 - Therapeutic agent for keratoconjunctival disorder: An object of the present invention is to research a new medicinal use of E-4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy) benzyloxyimino]-4-phenylbutyric acid, Z-2-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy) benzyloxyimino]-2-(4-phenoxyphenyl)acetic acid, 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy] benzoic acid, 2(S)-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl] propionic acid, or a salt thereof. Any of the above-mentioned carboxylic acid compounds and a salt thereof exhibit an excellent improving effect on corneal disorder models... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080070959 - Guanylhydrazone compounds, compositions, methods of making and using:

20080070960 - Novel 3-aryl-1,2-benzisoxazole derivatives and use thereof as medicinal products against cancer:

20080070961 - Polymorphs of n-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)-amino]sulfonyl}-2-thiophene-carboxamide: N-(2-acetyl-4,6-dimethylphenyl)-3-([(3,4 dimethyl-5-isoxazolyl)aminosulfonyl}-2-thiophenecarboxamide, is provided here in the form of three polymorphs (Forms A, C and E). Forms A, C and E are specified by their peaks in their X-ray powder diffraction patterns, their absorption peaks in their infrared absorption spectra in potassium bromide, their peaks in their Raman absorption spectra,... Agent: Jones Day

20080070962 - Derivatives of n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, their preparation and their application in therapeutics: (

20080070963 - Compositions and methods for promoting neural regeneration: The present invention relates to compositions and methods for promoting tissue regeneration, preferably neural tissue regeneration. Compositions of the invention include (i) certain diphenyl sulfides, diphenyl sulfoxides, diphenyl sulfones, and sulfide, sulfoxide and sulfones of dibenzothiophene and thioxanthene, as well as various analogues and derivatives of these compounds; (ii) one... Agent: Veronica Mallon

20080070964 - Opioid receptor active compounds: wherein R1 to R4 and n have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods... Agent: Schwegman, Lundberg & Woessner, P.A.

20080070965 - Thiophene-carboxamides useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, or disorders. The invention also relates to processes for preparing compounds of... Agent: Vertex Pharmaceuticals Inc.

20080070966 - Anti-microbial compositions: Anti-microbial compositions comprising certain imidazolium ionic liquids and non-ionic or anionic surfactants and methods of using said compositions in the preservation of personal care and cosmetic applications are provided.... Agent: Joann Villamizar Ciba Corporation/patent Department

20080070967 - Novel crystal forms of substituted phenylalkanoic acids and process for producing the same: t

20080070968 - Hexahydro-cycloheptapyrazole cannabinoid modulators:

20080070969 - [3.2.0] heterocyclic compounds and methods of using the same: Compounds of Formulae I-VI and derivatives thereof having anti-cancer, anti-inflammatory, and anti-microbial properties and to compositions that include one or more of compounds and their derivatives or analogs having anti-cancer, anti-inflammatory and anti-microbial properties are disclosed. Pharmaceutical compositions comprising such compounds and methods of treating cancer, inflammatory conditions, and microbial... Agent: Knobbe Martens Olson & Bear LLP

20080070970 - Novel indole derivatives as selective androgen receptor modulators (sarms): The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.... Agent: Philip S. Johnson Johnson & Johnson

20080070971 - Medical use of bilirubin and its structural analogues: Formulations and methods for preventing, inhibiting or controlling metabolic disorder, age-related disease and acute inflammations have been developed. The compositions comprise of bilirubins, bilirubin derivatives, their tetrapyrrolic analogues, tripyrroles, and dipyrroles. The compositions can be administered as a dosage form for oral ingestion, injection, suppository, or topical application. The effective... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080070972 - Controlled release formulations: The invention relates to a controlled release formulation for an oral cytokine inhibitor of interleukin-1 beta converting enzyme.... Agent: Miller, Canfield, Paddock And Stone P.L.C C/o Jonathan P. O'brien Ph.d.

20080070973 - Compounds having activity at the glyt1 transporter: The succinate and napadisylate salts and solvates of 2-(Methyloxy)-N-[2-methyl-1-phenyl-2-(1-pyrrolidinyl)propyl]-4,6-bis(trifluoromethyl)benzamide, 6-bis(trifluoromethy)benzamide napadisylate, and uses thereof in the treatment of disorders relating to GlyT1 transporter, such as schizophrenia, are disclosed.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080070974 - Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof: e

20080070975 - Formulations for parenteral delivery of compounds and uses thereof: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.... Agent: Choate, Hall & Stewart LLP/wyeth

20080070976 - Thiophene hydroxamic acid derivatives and their use as hdac inhibitors: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080070977 - Method and composition of a medicament to decrease the adverse events of olistat, an oral lipase inhibitor: A medicament to decrease the adverse events of Olistat, an oral lipase inhibitor, arranged in combination with Olistat, comprising: an emulsifier, a bowel relaxant and one or more chelating agents to absorb and mechanically agitate non-digested fats.... Agent: D. N. Halgren

20080070978 - Internal 1,15-lactones of fluprostenol and related prostaglandin f2a analogs and their use in the treatment of glaucoma and intraocular hypertension: Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into ophthalmic solutions and topically applied for the treatment of the increased intraocular pressure caused by glaucoma and the reduction... Agent: Dickinson Wright PLLC

20080070979 - Method for promoting gastrointestinal bicarbonate secretion: v

20080070980 - Use of beta-cryptoxanthin: β-Cryptoxanthin and esters thereof may find use for promoting an increased protein formation and/or prevention of loss of proteins in humans and animals.... Agent: Nixon & Vanderhye, PC

20080070981 - Water-soluble compositions of bioactive lipophilic compounds: wherein: X is a residue of a hydrophobic moiety, Y is a residue of a hydrophilic moiety, p is 1 or 2, m is 0 or 1, and n is an integer greater than or equal to 0 are disclosed. The lipophilic compound is preferably selected from the group consisting... Agent: Morgan, Lewis & Bockius LLP (sf)

20080070982 - System and methods of melanoma prevention: Inhibiting the enzymic action of tyrosinase in the melanocyte prior to, during, or after ultraviolet (UV) radiation exposure, including over-exposure causing erythema, or sunburn, prevents the production of melanin and thereby melanoma. Melanoma can be prevented by using a tyrosinase inhibitor agent that inhibits the enzymic action of tyrosinase to... Agent: Valauskas & Pine LLC

20080070983 - 2-o- (beta-d-glucopyranosyl) ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it: The composition comprising the novel compound 2-O-(β-D-glucopyranosyl)ascorbic acid has been extracted from plants such as from Ningxia Lycium barbarum L. and/or Lycium chinense Mill. The compositions comprising 2-O-(β-D-glucopyranosyl)ascorbic acid may be enzymatically synthesized using β-D-glucosyltransferase. Pure 2-O-(β-D-glucopyranosyl)ascorbic acid may be produced from such compositions. Alternatively, 2-O-(β-D-glucopyranosyl)ascorbic acid may be produced... Agent: Drinker Biddle & Reath (dc)

20080070984 - Compositions and methods of treating schizophrenia: Compositions and methods of treating both the positive and negative or cognitive symptoms of schizophrenia are disclosed. More specifically, pharmaceutical compositions for oral administration comprising at least one antipsychotic agent in an amount that is effective for treating a positive symptom of schizophrenia and at least one colonically absorbable form... Agent: Timothy A. Worrall Dorsey & Whitney LLP

20080070985 - Anti-bacterial compounds: wherein R1 is selected from OH, NH2 and NH3+X−, wherein X is an inorganic anion, wherein R2 is a singly-branched saturated or unsaturated aliphatic hydrocarbon moiety selected from C7-C15, wherein R5 is selected from H, and a linear saturated or unsaturated aliphatic hydrocarbon moiety selected from C6-C14, and wherein R2... Agent: Curatolo Sidoti Co., Lpa

20080070986 - Alkylether citrates for selectively cleaning the skin: The invention relates to the use of alkylether citrates in cosmetic and pharmaceutical preparations for protecting and maintaining the natural skin/mucous membrane microflora and the microbial skin/mucous membrane ecosystem without impairing the natural balancing processes which limit the number of pathogenic bacteria so that they do not become disease-inducing.... Agent: Cognis Corporation Patent Department

20080070987 - Meta-xylylenediamine vanadate salts: e

20080070988 - Method of enhancing hair growth: wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is... Agent: Allergan, Inc.

20080070989 - Method of evaluating evenness of suplatast tosilate crystal, even crystal, and process for producing the same: Provided are a method for evaluating evenness of suplatast tosilate crystals; stable suplatast tosilate crystals exhibiting evenness in optical purity; and a method for producing the suplatast tosilate crystals. The method for evaluating evenness of suplatast tosilate crystals includes: (a) a step of adding a solvent to suplatast tosilate crystals... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080070990 - Use of ractopamine enantiomers: A method of promoting or improving the feed efficiency and the muscle to fat ratio livestock animal by administering to the animal a therapeutically effective amount of a pure or substantially pure RR-enantiomer of ractopamine. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean... Agent: Howrey LLP

20080070991 - Animal product enrichment using resveratrol: The methods and systems disclosed herein include combining resveratrol with a bioavailability promoter to produce a bioavailable resveratrol, combining the bioavailable resveratrol with a combination compound to produce a bioavailable resveratrol enriched compound, and combining the bioavailable resveratrol enriched compound with an animal delivery method to produce a resveratrol enriched... Agent: Strategic Patents P.C..

20080070992 - Method for preparing solubilized composition containing oil-soluble substance: e

20080070993 - Additives for cosmetic products and the like: The present invention provides additives for cosmetic compositions. The additives chitosan based compositions, hyaluronic acid based compositions and/or poly Y glutomic acid based compounds. The cosmetic composition can be used in a variety of cosmetic properties.... Agent: Thomas A. O'rourke Bodner & O'rourke

20080070994 - Fibers and nonwovens from plasticized polyolefin compositions: The present invention relates to fibers and nonwovens made from plasticized polyolefin compositions comprising a polyolefin and a non-functionalized hydrocarbon plasticizer.... Agent: Exxonmobil Chemical Company

20080070996 - Chondroitin synthase and nucleic acid encoding the enzyme: A human-derived novel chondroitin synthase, which is an enzyme for synthesizing a fundamental backbone of chondroitin and has both glucuronic acid transferring activity and N-acetylgalactosamine transferring activity.... Agent: Sughrue Mion, PLLC

20080070995 - Methods and compositions relating to alzheimer's disease: Methods and compositions relating to Alzheimer's disease are provided. Specifically, proteins that are differentially expressed in the Alzheimer's disease state relative to their expression in the normal state are provided. Proteins associated with Alzheimer's disease are identified and described. Methods of diagnosis of Alzheimer's disease using the differentially expressed proteins... Agent: Dann, Dorfman, Herrell & Skillman

20080064626 - Methods of treating tendonitis in a subject by using an anti-cytokine agent: A method for treating tendonitis and bursitis in a subject involves providing an effective amount of an anti-cytokine agent to a musculo-tendinious structure. Anti-cytokine agents, such as, TNF-α inhibitors, NF-κB inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, IL-12 inhibitors, IL-15 inhibitors, IL-10, Interferon-gamma (IFN-gamma) act to prevent further inflammation initiated... Agent: Fox Rothschild, LLP

20080064628 - Fibrinogen targetting microparticles for promoting haemostasis: The present invention provides an injectable pharmaceutical product comprising an agent, the agent comprising an insoluble carrier to which is bound a peptide, the peptide being capable of binding fibrinogen such that the agent binds via the bound fibrinogen to activated platelets in preference to inactive platelets, and wherein the... Agent: Seed Intellectual Property Law Group PLLC

20080064646 - Lactobacillus fermentum n-desoxyribosyl transferases and the use thereof for enzymatic synthesis of 2', 3' - didesoxynucleosides and 2',3'- didehydro-2',3'- didesoxynucleosides: The inventive method for evaluating an X protein encoded by an Lactobacillus fermentum (L. fermentum ) ntd gene in such a way that the characteristics thereof are modified consists a) in obtaining the Lactobacillus fermentum (L. fermentum ) ntd gene mutants by random mutagenesis, b) in transforming cells containing a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080064648 - Methods and compositions relating to lipid accumulation: In general, this invention relates to nucleic acid and amino acid sequences involved in lipid accumulation, screening methods for identifying genes that regulate lipid accumulation, and the use of these sequences as targets for the diagnosis, treatment, and prevention of obesity and obesity-related diseases.... Agent: Clark & Elbing LLP

20080064647 - Prna chimera: A polyvalent multimeric complex formed from a plurality of circularly permuted chimeric pRNA molecules, each carrying a stabilized biologically active moiety.... Agent: Mueting, Raasch & Gebhardt, P.A.

20080064656 - Improvement of intestinal barrier integrity: The invention concerns a method for stimulating barrier integrity in a mammal by administering to a mammal a composition comprising: cicosapentacnoic acid (EPA), docosahexacnoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.... Agent: Foley And Lardner LLP Suite 500

20080064659 - Epoxyketone-based immunoproteasome inhibitors: An efficient new route for the preparation of dihydroeponemycin, an active eponemycin derivative, is provided, which includes the synthesis of the intermediate compound, a hydroxymethyl-substituted enone. In addition, a method is provided for synthesizing inhibitors, which includes PI′-modified analogues. These analogues selectively bind to a major immunoproteasome catalytic subunit LMP2... Agent: Stites & Harbison PLLC

20080064627 - Method for stimulating wound healing: The present invention relates to a method for stimulating wound healing, and more particularly to a method for stimulating wound healing in a subject in need thereof, comprising administering to a wound of the subject an effective amount for stimulating wound healing of a composition, wherein the composition comprises p43... Agent: Seed Intellectual Property Law Group PLLC

20080064629 - Amphiregulin as a protective agent in acute hepatic injury: The invention relates to the use of amphiregulin in the production of a medicament which can be used to treat acute hepatic injury and which is administered, for example, in order to: promote a primary endogenous protective reaction in the hepatic tissue against acute hepatic injury, promote DNA synthesis in... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080064632 - Combination therapy for the treatment of obesity: The present invention relates to compositions comprising PYY, PYY3-36, or a PYY agonist, and an anti-obesity agent, useful for the treatment and prevention of obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by... Agent: Merck And Co., Inc

20080064634 - Combination therapy for treatment of cancer: The invention relates to compositions and methods for treating diseases. In particular aspects, the invention relates to administering a combination of a disintegrin with a microtubule stabilizing agent useful for treatment of cancer.... Agent: Foley & Lardner LLP

20080064635 - Infant formulas for early brain development: Disclosed are infant formulas comprising at least about 6.5 g/L, on an as-fed basis, of an enriched whey protein concentrate, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. The formulas also typically include... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20080064640 - Mixture for transdermal delivery of low and high molecular weight compounds: The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed.... Agent: Knobbe Martens Olson & Bear LLP

20080064636 - Modification of feeding behaviour: The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and/or increase energy expenditure.... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080064630 - Osteogenic growth peptide fusion proteins: Fusion protein comprising a protein to be fused, e.g. a therapeutic protein fused to the C-terminal of osteogenic growth peptide (OGP). The fusion proteins have a prolonged circulation time.... Agent: Novo Nordisk, Inc. Patent Department

20080064637 - Prevention and reduction of blood loss: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary... Agent: Fish & Richardson PC

20080064638 - Proteins related to schizophrenia and uses thereof: Presenilin Associated Membrane Protein (PAMP), and nucleic acids encoding this protein, are provided. PAMP and PAMP nucleic acids provide diagnostic and therapeutic tools for evaluating and treating or preventing neurodevelopmental and neuropsychiatric disorders. In a specific embodiment, mutations in PAMP are diagnostic for schizophrenia. The invention further relates to screening,... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080064631 - T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease: The specification describes the sequences for two T-cell receptors—one having a high affinity and one having low affinity for the HLA-A2-restricted peptide PR1. Use of the T-cell receptors and variants thereof in the diagnosis and treatment of cancer and immune-related diseases are also provided.... Agent: Fulbright & Jaworski L.L.P.

20080064639 - Tryptophanyl-trna synthetase-derived polypeptides useful for the regulation of angiogenesis: The invention provides a method for inhibiting ocular neovascularization in a patient. The method comprises administering to a patient an ocular neovascularization inhibiting amount of a water-soluble polypeptide selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 7, and an ocular neovascularization inhibiting fragment thereof, which... Agent: Olson & Cepuritis, Ltd.

20080064633 - Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions: Method for treatment of inflammatory and fibrotic conditions in vivo using pure rhUG is disclosed. Method for treating or preventing inflammatory or fibrotic conditions characterized by a deficiency of endogenous functional UG is also disclosed. Compositions containing pure rhUG, optionally also containing lung surfactant, and assay procedures for detection of... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20080064641 - Novel peptide and pharmaceutical composition containing said peptide: The invention relates to a novel peptide, a pharmaceutical composition containing said peptide and to the use of said composition for treating various skin alternations. More particularly, the treatment of said alterations consists in reinforcing the derma-epidermal junction and the cell-matrix and/or cell-cell adherence of epidermis and in promoting the... Agent: Foley And Lardner LLP Suite 500

20080064643 - Myd88 homodimerization inhibitors: in which the various groups are defined in the description here below, which mimic a particular protein portion of MyD88, preventing its homodimerisation and interfering with its interaction with the TIR domain. The present invention also provides procedures for the preparation of said compounds, pharmaceutical compositions containing them and their... Agent: Nixon & Vanderhye, PC

20080064642 - Peptidic and peptidoid bradykinin b1 receptor antagonists and uses thereof: The present invention provides for new peptidic and peptidoid Bradykinin B1 receptor antagonists of formula (1) having good to excellent affinities and selectivity for the BKB1 receptor, and increased resistance to enzymatic degradation, superior pharmacokinetic properties, both in vitro and in vivo, with capability to significantly prevent and treat conditions... Agent: David S. Resnick

20080064644 - Serum-free cell culture medium for mammalian cells: This invention relates to a process for the manufacturing of a protein in mammalian cells cultured in a serum-free medium.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080064645 - Non-natural sphingolipid analogs and uses thereof: This disclosure provides a composition useful for inhibiting caveolar endocytosis, plasma membrane microdomain formation, virus binding and infection, transmembrane signaling, and integrin function in cells. The composition is composed of non-natural analogs of sphingolipids, and may have applications in the treatment or amelioration of diseases associated with caveolar endocytosis, plasma... Agent: Fish & Richardson P.C.

20080064649 - Hematopoietic growth factor inducible neurokinin-1 gene and uses thereof: The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is... Agent: Licata & Tyrrell P.C.

20080064652 - Methods and compositions for treating hypercholesterolemia: The present invention provides methods and compositions for treating hypercholesterolemia using therapeutic apoE proteins. A therapeutic apoE protein is a naturally-occurring apoE protein (e.g., apoE1, apoE2, apoE2*, apoE2**, apoE3, and apoE4) that has one or more amino acid substitutions in the carboxy-terminal region which, when administered to a mammal having... Agent: Clark & Elbing LLP

20080064650 - Therapeutic uses of inhibitors of rtp801l: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.... Agent: Cooper & Dunham, LLP

20080064651 - Trpm-2 antisense therapy: It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be applied in treatment of prostate cancer and renal cell cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo... Agent: Marina Larson & Associates, LLC

20080064654 - Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects: Methods are presented that comprise the administration of a pharmaceutical composition comprising adenosine and dipyridamole, as well methods comprising the combined administration of dipyridamole administered as a bolus with adenosine given as an infusion, both at dosages below their respective single agent dosages, for detecting the presence and/or assessing the... Agent: Dechert LLP

20080064653 - Use of adenosine a2a modulators to treat spinal cord injury: The present invention is a method for treatment or prevention of injury to nerve cells. The method can use at least one A2A receptor modulator to prevent injury to or enhance the healing of the injured cells.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080064655 - Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis b: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-axyl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The... Agent: Jones Day

20080064657 - Isomaltooligosaccharides from leuconostoc as neutraceuticals: Isomaltooligosaccharides (IMOs) produced by Leuconostoc mesenteroides ATCC 13146 fermentation with a sucrose:maltose ratio of 2:1 have been discovered to be effective prebiotics in mixed cultures of microbial populations, including cultures from chicken ceca. Surprisingly in mixed microbial cultures this IMO composition proved as effective as FOS. Thus, these IMOs can... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20080064658 - Use of isomaltooligosaccharides to decrease abdominal fat: Isomaltooligosaccharides (IMOs) produced by Leuconostoc mesenteroides ATCC 13146 fermentation with a sucrose:maltose ratio of 2:1 have been discovered to be effective prebiotics in mixed cultures of microbial populations, including cultures from chicken ceca. Surprisingly in mixed microbial cultures this IMO composition proved as effective as FOS. Thus, these IMOs can... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20080064660 - Modulation of inflammation related to columnar epithelia: This invention provides pharmaceutical compositions containing lipoxin compounds and therapeutic uses for the compounds in treating or preventing a disease or condition associated with columnar epithelial inflammation. The invention also discloses methods for screening for compounds useful in preventing columnar epithelial inflammation.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080064661 - Dihydroxyl compounds and compositions for cholesterol management and related uses: The present invention relates to novel dihydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence,... Agent: Pharmacia & Upjohn

20080064662 - Methods and compositions for modulating sphingosine -1- phosphate (s1p) receptor activity: The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.... Agent: Lahive & Cockfield, LLP

20080064663 - Melt processing of phosphoroamido(di)thioate insecticides: An insecticide solid or particulate is produced from a phosphoroamido(di)thioate insecticide such as acephate. The particulate insecticide is formed by melting the insecticidal solids in a substantially oxygen-free, and preferably moisture free, atmosphere to prevent oxygen entrainment in the resulting melt to inhibit later degradation upon storage. The melt is... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080064664 - Skin beautifier: A skin beautifier contains sphingomyelin, which is a phospholipid, as an effective ingredient. In addition, skin-beautifying food or feed contains sphingomyelin as an effective ingredient. The present invention provides a skin beautifier and skin-beautifying food or feed supplying effects on beauty, such as skin-moisturizing and protecting effects, skin-roughness-preventing and improving... Agent: Townsend & Banta C/o Portfolio Ip

20080064665 - Combination approaches to cancer treatment: wherein X represents at any available ring position —CONH—, —SO2NH—, —O—, —CH2—, NHCO— or —NHSO2—; R represents a lower C1-6 alkyl optionally substituted with one or more groups including hydroxyl, amino and N-oxides therefrom or dialkylamino and N-oxides therefrom; Y represents at any available ring position —N-aziridinyl, —N(CH2CH2W)2 or —N(CH2CHMeW)2,... Agent: Nixon & Vanderhye, PC

20080064666 - Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise... Agent: Seed Intellectual Property Law Group PLLC

20080064667 - Oxazole derivatives of tetracyclines: e

20080064668 - 1,3-diacylated, 26,27-alkyl/haloakyl vitamin d3 compounds and methods of use thereof: The invention provides (1,3)di-acylated vitamin D3 analogs of cholecalciferol, substituted at carbon (20) with methyl or cyclopropyl wherein carbon (16) is a single or double bond, and carbon (23) is a single, double, or triple bond. Various alkyl or haloalkyl substitutions are incorporated at carbon (25). The invention provides pharmaceutically... Agent: Edwards Angell Palmer & Dodge LLP

20080064669 - Stable pharmacologically active compositions including vitamin d-containing and corticosteroid compounds with low ph compatibility: Provided are pharmaceutical compositions comprising at least one vitamin D-containing compound, at least one corticosteroid compound, and at least one solvent component selected from the group consisting of triglycerides, sorbitan, sorbitan fatty esters, cetearyl glucoside, PEG-n sorbitan stearate, acrylamide/sodium acryloyldimethyl taurate copolymers, and mixtures thereof. Also provided are methods of... Agent: Kenyon & Kenyon LLP

20080064670 - Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080064671 - Combinations containing a 4-acylaminopyridine derivative: The instant disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system. The disclosure includes compositions and methods based on use of a 4-acylaminopyridine derivative in combination with one or more other neurogenic agents. One 4-acylaminopyridine derivative is MKC-231.... Agent: Townsend And Townsend And Crew, LLP

20080064672 - Compositions containing topical active agents and pentyleneglycol: Disclosed are cosmetic and dermatological compositions containing a steroid hormone or anti-inflammatory agent and pentylene glycol.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080064673 - Cyanopyrrole-phenyl amide progesterone receptor modulators and uses thereof: s

20080064674 - Pharmaceutical compositions: Disclosed are metered dose inhalers having a metering valve to deliver a dose containing an aerosol suspension formulation, said aerosol suspension formulation comprising: an effective amount of Mometasone Furoate, Formoterol or a combination thereof; a suspension medium selected from the group consisting of 1,1,1,2,3,3,3,-heptafluoropropane, 1,1,1,2-tetrafluoroethane; and a solvent that is... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080064675 - Use of aromatic flavoring agents with high melting point as solubilizing agents: The present invention relates to the use of aromatic flavoring compounds having a high melting point as solubilizing agents or crystallization inhibitor agents of insoluble or poorly-water soluble biologically active ingredients in pharmaceutical and agrochemical compositions. Additionally, the present invention also relates to pharmaceutical compositions containing aromatic flavoring compounds with... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080064676 - Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity: Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.... Agent: Pepper Hamilton LLP

20080064677 - S1p receptor modulating compounds and use thereof: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune... Agent: Goodwin Procter LLP Patent Administrator

20080064678 - 2-(1-oxo-1h-isoquinolin-2-yl)acetamide derivatives: e

20080064679 - Water soluble cannabinoids: Water-soluble cannabinoid compounds that are agonists of CB1 and CB2 cannabinoid receptors are provided. The compounds are made water-soluble by derivatization of the alkyl side chain and/or the phenolic hydroxyl group of tetrahydrocannabinol. The water-soluble cannabinoids are useful for the treatment of appetite loss, pain, multiple sclerosis, nausea and vomiting,... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080064680 - Methods for diagnosis and treatment of cancer: The present application discloses methods of detecting and treating cancer which express MUC1 aberrantly.... Agent: Jhk Law

20080064682 - Pyrazole derivatives: (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, a sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080064681 - Therapeutic agent for treating glaucoma: h

20080064684 - 1-aryl- or 1-alkylsulfonyl-heterocyclybenzazoles as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20080064683 - Inhibition of vegf translation: In accordance with the present invention, methods for inhibiting the translation of VEGF and methods for decreasing VEGF level by inhibiting VEGF translation are provided. In another aspect of the invention, compounds that inhibit the 5′-UTR-dependent translation of VEGF and methods for identifying such compounds are provided.... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20080064685 - Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof:

20080064686 - Novel soluble 1,4 benzodiazepine compounds and stable salts thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation... Agent: Medlen & Carroll, LLP

20080064687 - Novel thiourea derivatives and the pharmaceutical compositions containing the same: The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080064689 - 3-[4-(6-pyridin-3-yl)-3-phenyl] -5-(1h-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents: Compounds of the formula (I): or a pharmaceutically-acceptable salt or pro-drug thereof: wherein R1 is selected for example from hydrogen, halogen, optionally substituted methyl; R2 and R3 are independently selected from hydrogen, fluoro, chloro and trifluoromethyl; R4 and R5 are independently selected, for example, from hydrogen, methyl, optionally substituted (2-4C)alkyl,... Agent: Morgan Lewis & Bockius LLP

20080064688 - Anti-inflammatory medicaments: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.... Agent: Hovey Williams LLP

20080064690 - Pyrazole-amides and -sulfonamides: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides pyrazole-amides and -sulfonamides, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly... Agent: Townsend And Townsend And Crew, LLP

20080064691 - Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity: A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; wherein, for example, Z is CH or nitrogen, R4 and R5 together are either —S—C(R6)═C(R7)— or —C(R7)═C(R6)—S—; R6 and R7 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy and carbamoyl; A... Agent: Astrazeneca R&d Boston

20080064692 - Fungicidal mixtures: in a synergistically effective amount, methods for controlling phytopathogenic harmful fungi using mixtures of the compound I with the compounds II and the use of the compound I and the compounds II for preparing such mixtures, and also compositions comprising these mixtures are described.... Agent: Birch Stewart Kolasch & Birch

20080064694 - Multi-phase release methscopolamine compositions: Formulations have been developed administering methscopolamine in multi-phases. In a preferred embodiment, the formulation contains methscopolamine in an immediate release. (“IR”) form and a sustained or delayed release (“DR”) form and/or poised release (“PR”) form. In another embodiment, the methscopolamine is released in a gradient, decreasing the side effects associated... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080064693 - N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors: The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1, 2, 3, or 4; Z represents O, S, NR6, SO or SO2; R1 represent hydrogen, cyano, hydroxy, or C1-4alkyl optionally substituted with halo, R2 represents hydrogen, C1-4alkyl, or C1-4alkyloxy-; R3 represents hydrogen,... Agent: Philip S. Johnson Johnson & Johnson

20080064695 - Pyrrole derivatives and their methods of use: The invention relates to a series of substituted pyrrole derivatives, compositions comprising the same, and methods of treating conditions and disorders using such compounds and compositions.... Agent: Robert Deberardine Abbott Laboratories

20080064697 - Pyridine, quinoline and pyrimidine derivatives: wherein A, R1 to R5 are as defined in the specification and G is a pyridine, quinoline or pyrimidine group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080064696 - Substituted sulphoximines as tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same: in which A, E, G, X, R1, R2, R3, R4, R5, R6, R7, R8, m, p, q, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted sulphoximines, to methods of preparing said substituted sulphoximines as well as the use thereof for manufacturing a pharmaceutical composition... Agent: Millen, White, Zelano & Branigan, P.C.

20080064698 - 1-phenyl and 1-pyridylpyrazole derivatives and their use as pesticides: The invention relates to 1-(2,4,6-trisubstituted-phenyl)-5-amino-4-substituted-pyrazole derivatives of formula (I) or salts thereof wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use for the control of pests (including arthropods and helminths).... Agent: Buchanan, Ingersoll & Rooney PC

20080064699 - Novel compounds as cannabinoid receptor ligands and uses thereof: e

20080064700 - Aryl triazines as lpaat-beta inhibitors and uses thereof: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.... Agent: Seed Intellectual Property Law Group PLLC

20080064701 - Anti-diabetic combinations: The invention discloses a method of administering an anti-diabetic combination comprising a DPP inhibitor and a slow release biguanide to a mammal in need of thereof. This invention further discloses anti-diabetic combination comprising a DPP inhibitor and a slow release biguanide for treating diabetes.... Agent: Ramesh Sesha

20080064702 - Use of folates for the prevention and treatment of vascular diseases: This invention relates to the use of folates for the prevention and/or treatment of cardiovascular diseases, such as atherosclerosis, and in particular for modulating endothelial nitric oxide synthase (eNOS). The invention further relates to pharmaceutical preparations consisting of said folates and a pharmaceutically acceptable carrier, optionally in combination with other... Agent: Millen, White, Zelano & Branigan, P.C.

20080064703 - Fused bicycloheterocycle substituted quinuclidine derivatives: i

20080064704 - 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors: The invention relates to novel heterocyclic derivatives of the general formula (I), processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.... Agent: Jeffrey M. Greenman

20080064705 - Theophylline-based nitophenylpiperazine derivatives for enhancing aortic smooth muscle relaxation: e

20080064706 - Piperidine derivatives as histamine h3 receptor ligands: Compounds of formula: wherein Ar1 and Q are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the treatment of depression.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080064707 - Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same: in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted arylpyrazolopyridines, to methods of preparing said substituted arylpyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the... Agent: Millen, White, Zelano & Branigan, P.C.

20080064708 - Substituted pyrazinecarboxylic acid anilde dervatives or salts thereof, intermediates of the same, pesticides for agricultural and horticultural use, and usage thereof: wherein R1 is H, C1-6 alkyl, halo C1-6 alkyl, or the like; R2 is halogeno, C1-6 alkyl, or the like; G is C2-10 alkyl or the like; Z is oxygen or sulfur; X's are each independently H, halogeno, or the like; Y's are each independently H, halogeno, cyano, or the... Agent: Manelli Denison & Selter

20080064709 - Methods and compositions for the treatment of vascular depression: Methods and compositions are provided for treating vascular depression. The methods involve administering to a subject in need thereof a xanthine derivative in a therapeutically effective amount to treat vascular depression, particularly the xanthine derivatives pentoxifylline or propentofylline. The methods may further include administration of an additional therapeutic agent in... Agent: Alston & Bird LLP

20080064710 - Novel hydantoin derivatives for the treatment of obstructive airway diseases: The invention provides compounds of formula (I), wherein R1 and R2 are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.... Agent: Fish & Richardson P.C.

20080064711 - Composition for treating oral cavity and mucousal infections: The present invention provides a composition of matter for treating oral cavity infections and mucosal infections, said composition comprising: at least one anti-microbial drug; and at least one essential oil, in combination with a substantially, alcohol-free carrier system, said carrier system being selected from an isotonic system and a moderately... Agent: Townsend And Townsend And Crew, LLP

20080064712 - Morphinan derivatives, the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof: The present invention relates to a class of morphinan compounds and quaternary ammonium salts thereof, substituted in Position 14, which may be used as highly active analgesics or also as opioid antagonists. The present invention also relates to the pharmaceutically acceptable salts and easily produced derivatives thereof, a process for... Agent: Cohen, Pontani, Lieberman & Pavane

20080064713 - Dry syrup containing loratadine: Dry syrup preparations comprising loratadine as a hydrophobic medicinal drug are provided. The loratadine dry syrup preparations can be produced using a cellulose material or an argininic acid salt together with sugar.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080064714 - Novel pyrrolodihydroisoquinolines: The invention relates to novel pyrrolodihydroisoquinoline derivatives which are efficacious inhibitors of cellular (hyper)proliferation and/or inducers of apoptosis in cancer cells.... Agent: Nath & Associates PLLC

20080064715 - 6-azaindole compound: wherein R1, R2, R3 and R6 are the same or different and each is a hydrogen atom or a substituent; one of R4 and R5 is a hydrogen atom and the other is a group represented by the formula: —C(═X)—R7 wherein X is N—O—R8 or N—NH—R9 wherein R8 and R9... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080064716 - Biphenyl integrin antagonists: e

20080064717 - Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme:

20080064718 - Inhibitors of protein tyrosine kinase activity: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly,... Agent: Keown & Zucchero, LLP

20080064719 - Crf receptor antagonists and methods relating thereto: i

20080064720 - 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors: The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for the treatment of VLA-4 dependent inflammatory diseases such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory... Agent: Hoxie & Associates LLC

20080064722 - Agent for promoting interferon-y production: The object of the present invention is to provide an agent for promoting IFN-γ production, which can be safely applied to living bodies; the present invention solves the problem by providing an agent for promoting IFN-γ production, which comprises a tri-heterocyclic polymethine cyanine dye(s), and a method for producing IFN-γ,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080064721 - Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy: A composition for treating, controlling, reducing, ameliorating, or preventing allergy comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an anti-allergic medicament and/or an additional anti-inflammatory agent and can be formulated for topical application,... Agent: Bausch & Lomb Incorporated

20080064723 - Anti-hair graying agent: An anti-hair graying agent containing, as an active ingredient, a substance having a superior anti-hair graying action, for example, aminocyclohexane carboxylic acid, aminocyclohexane carboxylic acid esters such as aminocyclohexane carboxylic acid ethyl ester, aminocyclohexane derivatives such as aminocyclohexanol, and piperidinecarboxylic acid, piperidinecarboxylic acid esters such as piperidinecarboxylic acid ethyl ester,... Agent: Snider & Associates

20080064724 - Composition comprising methylphenidate and another drug: A process of treating a subject that is undergoing methylphenidate therapy and concomitant therapy with another drug undergoes or interferes with P450 metabolism wherein the methylphenidate is d-threo-methylphenidate.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080064725 - Intrathecal administration of triptan compositions to treat non-migraine pain: Intrathecal delivery of a pharmaceutically acceptable formulation for intrathecal administration of any drug selectively binding to this receptor to provide pain can be used in any situation in which intrathecal (“IT”) drugs are presently used for pain management. In the preferred embodiment, the drug is a triptan. In another embodiment,... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080064727 - Crystalline forms of tiagabine hydrochloride: The present invention provides 16 new crystalline forms of tiagabine hydrochloride.... Agent: Cephalon, Inc.

20080064726 - Pyrrolidine derivatives: e

20080064728 - Heterocyclic compounds useful as dpp-iv inhibitors: wherein Z, R —R and A have the meaning as cited in the description and the claims as examplified by the compound (II) said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.... Agent: Kilyk & Bowersox, P.l.l.c.

20080064729 - Phenethylamide derivatives with kinase inhibitory activity: The present invention provides novel phenethylamide compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20080064730 - Azine compounds for combating animal pests: The present invention relates to new azine compounds which are useful combating animal pests, in particular insects and nematodes and to the salts thereof. The invention also relates to a method for combating insects, nematodes and arachnids. The azine compounds of the invention are described by the general formula (I)... Agent: Hutchison Law Group PLLC

20080064731 - Remedy for chronic disease: A remedy and/or a preventive for a chronic disease which contains an EDG-2 antagonist. Because of binding to a subtype EDG-2 of LPA receptor, an EDG-2 antagonist is useful in treating and/or preventing chronic diseases (for example, diseases caused by the progress of chronic asthma, glomerular nephritis, obesity, arteriosclerosis, rheumatoid... Agent: Sughrue-265550

20080064732 - Substituted 4-hetarylpyrazolines: r

20080064733 - Small molecule inhibition of pdz-domain interaction: Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general... Agent: Townsend And Townsend And Crew, LLP

20080064734 - Anilinopyrazole derivatives useful for the treatment of diabetes: The present invention relates to anilinopyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders.... Agent: Jeffrey M. Greenman

20080064735 - Method for controlling harmful organisms in crops of useful plants: Method for controlling harmful organisms in genetically modified vegetable plants containing a gene derived from Bacillus thuringiensis, said gene encoding and expressing a protein with an insecticidal action, wherein an insecticidally active quantity of one or more compounds from the following groups (a) to (f) is applied to the plants,... Agent: Buchanan, Ingersoll & Rooney PC

20080064736 - Substituted 2-pyrrolidone derivatives as fungicides and insecticides: The use of a compound of formula (I) or a salt thereof, where the symbols have the meanings given in the description, for the control of phytopathogenic mircroorganisms of harmful animals.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080064737 - Creatine pyroglutamic acid salts and methods for their production and use in individuals: The present invention relates to a method of production and the use of a compositional ingredient. Specifically, the present invention relates to hydrosoluble stable organic salts of creatine and pyroglutamic acid. The compositional ingredient may be useful for the regulation of athletic and cognitive functions.... Agent: Torys LLP

20080064738 - Creatine pyroglutamic acid salts and methods for their production and use in individuals: The present invention relates to a method of production and the use of a compositional ingredient. Specifically, the present invention relates to hydrosoluble stable organic salts of creatine and pyroglutamic acid. The compositional ingredient may be useful for the regulation of athletic and cognitive functions.... Agent: Torys LLP

20080064739 - Creatine pyroglutamic acid salts and methods for their production and use in individuals: The present invention relates to a method of production and the use of a compositional ingredient. Specifically, the present invention relates to hydrosoluble stable organic salts of creatine and pyroglutamic acid. The compositional ingredient may be useful for the regulation of athletic and cognitive functions.... Agent: Torys LLP

20080064740 - Novel thiophene derivatives: The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.... Agent: Dickstein Shapiro LLP

20080064741 - Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA... Agent: Sughrue Mion, PLLC

20080064742 - Substituted benzopyrans as selective estrogen receptor-beta agonists: The present invention relates to novel benzopyran ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory, bowel disease, and arthritis. Formula (I),... Agent: Eli Lilly & Company

20080064743 - Dry powder compound formulations and uses thereof: The present invention provides lyophilized formulations comprising methylnaltrexone, and processes for preparation of provided formulations. Additionally provided are compositions and products containing the methylnaltrexone formulation, as well as methods for producing formulations, compositions and products. Provided formulations as well as compositions and products containing methylnaltrexone formulations are useful for preventing,... Agent: Choate, Hall & Stewart LLP/wyeth

20080064744 - 6-carboxy-normorphinan derivatives, synthesis and uses thereof: The present invention relates to compounds of formula I, synthesis thereof, and methods of using the same.... Agent: Choate, Hall & Stewart LLP/wyeth

20080064745 - Androgen modulators: The present invention is directed to the compound 4-(2-methoxy-phenoxy)-2-trifluoromethyl-benzonitrile, is use as an androgen modulator and to pharmaceutical compositions containing this compound.... Agent: Warner-lambert Company

20080064746 - Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases: The use of lipoxin analogs for the treatment or prevention of asthma and asthma related diseases is described. In particular, acetylenic lipoxin analogs are effective for the treatment and prevention of eosinophil recruitment involved with the inflammation processes associated with asthma, asthma like conditions, and lung injuries associated from airway... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080064747 - Prevention of neutrophil recruitment: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080064748 - Substituted enaminones, their derivatives and uses thereof: The invention relates to substituted enaminones of Formula I and their derivatives and the discovery that these compounds modulate the effect of γ-aminobutyric acid (GABA) on the GABAA receptor complex in a therapeutically relevant fashion and may be used to ameliorate CNS disorders amenable to modulation of the GABAA receptor... Agent: Heller Ehrman LLP

20080064749 - Lipoxin analogs as novel inhibitors of angiogenesis: The present invention is directed to methods for the prevention or inhibition of angiogenesis. The method is accomplished by the administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4, LXA4, 15-epi-LXA4 or 15-R/S-methyl, LXA4 and pharmaceutically acceptable salts, esters, amides, carboxylic acids, or prodrugs thereof, to a subject in need thereof.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080064750 - Fat composition: The invention provides a fat and oil composition which contains diacylglycerol at a high concentration recognized to have an action of suppressing the accumulation of body fat, has a low content of trans-unsaturated fatty acid having a risk of exerting an adverse influence on diseases in circulatory organs, and is... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080064751 - Regulation of phospholipase d activity: Novel inhibitors of polyisoprenyl phosphate signaling regulates phopholipase D activity.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080064752 - Acid addition salts of-5-aminolevulinic acid or its derivatives: The present invention provides an acid addition salt of 5-aminolevulinic acid (5-ALA) or of a 5-ALA derivative (e.g. a 5-ALA ester) with an acid which has a pKa of about 5 or less, preferably about 3 or less, with the proviso that the acid is other than hydrochloric acid. Particularly... Agent: Kenyon & Kenyon LLP

20080064753 - Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators: Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the... Agent: Knobbe Martens Olson & Bear LLP

20080064754 - Amino ion releasing hydrogen bonded molecule: A free amino ion releasing molecule useful for a wide variety of medical and cosmetic applications. The chemical name of the new molecule in acetate form name is 2-amino 5-triaminoguanidovalericbenzoicdiacetate, sometime referred to herein as Tri-Amino. Its chemical formula is C15H28N6O6. Its chemical structure is described in the drawings. Two... Agent: John R. Ross

20080064755 - Topical application of adapalene for the long-term treatment of acne vulgaris: Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two... Agent: Buchanan, Ingersoll & Rooney PC

20080064756 - Use of alcohol-oxyalkylates in the form of adjuvants for benzamidoxime fungicidal derivatives, appropriate agents and kits: m

20080064757 - Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal: Disclosed herein are novel antagonists of the androgen receptor and androgen receptor mutations associated with clinical failure of currently prescribed anti-androgens and use of said antagonists in the treatment of conditions associated with inappropriate activation of the androgen receptor.... Agent: Potter Anderson & Corroon LLP Attn: Kathleen W. Geiger, Esq.

20080064758 - Method of treatment or prophylaxis of depression: in which R1 represents hydrogen or halogen; R2 represents hydrogen, hydroxy, lower alkoxy, lower alkoxy substituted with one or two lower alkoxycarbonyl or carboxy groups, lower alkoxy substituted with lower alkylaminocarbonyl which may be substituted with lower alkoxy, lower alkoxy substituted with cyclic aminocarbonyl of 4 to 6 carbon atoms,... Agent: Foley And Lardner LLP Suite 500

20080064759 - Process for preparing fenofibrate compositions: The invention provides processes for producing fenofibrate compositions.... Agent: Venable LLP

20080064760 - Spontaneously dispersible pharmaceutical composition: A spontaneously dispersible pharmaceutical composition comprising a poorly soluble drug and a carrier medium comprising (1) a lipophilic component, (2) a surfactant, and optionally (3) a hydrophilic component, wherein at least one of the components (1) to (3) is solid at room temperature. A particularly useful hydrophilic component in the... Agent: Novartis Corporate Intellectual Property

20080064761 - O/w-gel-compositions having pentaerythriol esters or oligomers thereof: An oil and water gel composition is provided containing a polymer gel former of a polymer or copolymer of acrylic acid or acrylamide, a wax component having a melting point of at least 30° C. containing esters of pentaerythritol, dipentaerythritol and/or tripentaerythritol, and an oil component liquid at 25° C.... Agent: Cognis Corporation Patent Department

20080064762 - Composition comprising a pharmacologically active agent coupled to a target cell specific component, and a saponin: The present invention relates to a composition comprising a pharmacologically active agent coupled to a target cell specific component, and a saponin, to uses of said composition and to a kit comprising said composition. The invention also relates to a method of enhancing the function and/or the target cell specificity... Agent: Pearl Cohen Zedek Latzer, LLP

20080064763 - Pharmaceutical compositions with enhanced performance: Pharmaceutical compositions of a low-solubility drug and lower alkanoate-, phthalate- and trimellitate esters of hydroxypropyl methyl cellulose and lower alkanoate- and succinate esters of cellulose and methyl cellulose are disclosed that provide enhanced concentrations of the drug in a use environment.... Agent: Chernoff, Vilhauer, Mcclung & Stenzel

20080064765 - Novel hair growth compositions and methods for treating hair loss or related claims: The present invention relates to hair growth compositions as well as to methods for treating hair loss or related conditions.... Agent: Jacob Birnbaum

20080064764 - Calcium-sensing receptor 2 (car2) and methods for using: The current disclosure provide a novel human calcium sensing receptor named CaR2 and the nucleotide sequence that encodes the receptor. The disclosure further provides antibodies specific for CaR2. Also disclosed are methods of identifying modulators of the receptor and methods of using the identified modulators to treat calcium receptor mediated... Agent: Lahive & Cockfield, LLP

20080058245 - Vectors for recombinant protein expression in e. coli: The present invention relates to methods of providing a protein product to a customer. In particular, the invention relates methods of using protein expression vectors to produce proteins to be provided to a client. The invention also provides vectors for the cloning and expression of proteins, including reagent proteins and... Agent: Townsend And Townsend And Crew, LLP

20080058249 - Complexes: The invention relates to colloidal aqueous solutions of complexes between a charged peptide and a bilayer-forming galactolipid. The colloidal solutions can be used as a drug delivery system for the charged peptide in the treatment of infections, in wound healing and in other diseases.... Agent: Birch Stewart Kolasch & Birch

20080058250 - Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods: The present invention generally concerns the management of age-related diseases in domestic animals. Specifically, the present invention is directed to combination therapies for the treatment of progressive renal diseases (e.g., Chronic Renal Failure) and their accompanying secondary disease states. In a composition aspect, the present invention provides a composition comprising... Agent: Sheppard, Mullin, Richter & Hampton LLP

20080058254 - Composition and method for enhancing or promoting the activity of insulin, enhancing skeletal muscle growth, reducing skeletal muscle loss, and increasing the energy supply to skeletal muscle: A dietary supplement and method for enhancing or promoting the activity of insulin, enhancing skeletal muscle growth, reducing skeletal muscle loss, and increasing the energy supply to skeletal muscle of an individual comprising at least D-Pinitol and Leucine or derivatives thereof. The dietary supplement may further comprise at least one... Agent: Kenyon & Kenyon LLP

20080058269 - Insulin releasing peptides: The present invention relates to peptides, or fragments thereof, isolated from the skin secretions of amphibians and which act as stimulators of insulin secretion and pancreatic beta cell function. The invention also encompasses peptide having at least 80%, preferably at least 85%, more preferably at least 90%, optionally more than... Agent: Patent Administrator Kirkpatrick & Lockhart Nicholson

20080058272 - Nonamer peptides for cancer treatment: The present invention provides nonamer peptides derived from fibroblast activation protein α (FAPα) for the treatment of solid tumors. These peptides specifically bind to HLA, defined by an IC50 value of less than about 50 μM, induce a T cell response in a subject, wherein position No. 2 of said... Agent: Suzannah K. Sundby Smith, Gambrell & Russel, LLP

20080058275 - Rna interferases and methods of use thereof: The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to... Agent: Klauber & Jackson

20080058282 - Use of lactulose in the treatment of autism: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are... Agent: Vern Maine & Associates

20080058283 - Composition based on salts of hyaluronic acid for treating epithelial lesions: Compositions based on physiologically acceptable salts of hyaluronic acid having very low viscosity, usable for the treatment and prevention of epithelial lesions and lesions of the connective tissue.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080058246 - Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity: Methods are provided for the synthesis of polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and receptor-binding antagonists thereof, which conjugates retain unusually high receptor-binding activity. Preparation of polymer conjugates according to the methods of the present invention diminishes or avoids steric inhibition of receptor-ligand interactions that commonly results... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080058247 - Polynucleotides and polypeptides encoding receptors: Receptor polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing receptor polypeptides and polynucleotides in the design of protocols for the treatment of diseases and diagnostic assays for such conditions.... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080058248 - Toxin complex proteins and genes from xenorhabdus bovienii: The subject invention relates to novel Xenorhabdus toxin complex (TC) proteins and genes that encode these proteins. More specifically, the subject invention relates to TC genes and proteins obtainable from Xenorhabdus bovienii strain ILM104.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080058251 - Substituted nonadepsipeptides: The invention relates to nonadepsipeptides and methods for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.... Agent: Morrison & Foerster LLP

20080058252 - Use of c5a receptor antagonist in the treatment of fibrosis: This invention relates to the use of an antagonist of a G protein-coupled receptor in the prevention and/or treatment of fibrosis, such as the treatment of fibrosis associated with myocardial infarction or diabetes or certain pulmonary conditions. In a preferred embodiment, the antagonist is a C5a receptor antagonist, more preferably... Agent: Haynes And Boone, LLP

20080058253 - Deoxononadepsipeptides: The invention relates to nonadepsipeptides and methods for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.... Agent: Morrison & Foerster LLP

20080058264 - Amino-acid containing composition for inhibiting accumulation of fat: An amino-acid containing composition for inhibiting accumulation of fat, containing leucine in an amount of 33 to 67% by weight and threonine in an amount of 33 to 67% by weight, in terms of free amino acids thereof, based on whole amino acids.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080058267 - Apoptin-associating protein: The invention relates to the field of apoptosis. The invention provides novel therapies, for example, novel combinatorial therapies or novel therapeutic compounds that can work alone, sequentially to, or jointly with Apoptin, especially in those cases wherein p53 is completely or partially non-functional.... Agent: Trask Britt

20080058257 - Costimulatory molecules and uses thereof: The invention relates to a novel costimulatory pathway mediated by a member of the semaphorin protein family, Sema4A, which is selectively expressed on the surface of dendritic cells. In addition, the invention relates to the use of Sema4A protein and protein derivatives in a method for the identification of immunomodulatory... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080058255 - Glycosylation-disrupted factor vii variants: The present invention relates to human coagulation Factor VII polypeptides, as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions comprising Factor VII polypeptides, uses and methods of treatment; and any additional inventive features related thereto.... Agent: Novo Nordisk, Inc. Patent Department

20080058258 - Growth factor: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it,... Agent: Marshall, Gerstein & Borun LLP

20080058263 - Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins: The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth... Agent: Marshall, Gerstein & Borun LLP

20080058265 - Methods and compositions for activated protein c with reduced anti-coagulant properties: This invention relates to a novel form of protein C or activated protein C. More specifically, the invention is directed to a variant of protein C that is activated at a higher rate than wild-type or other variants and produces an activated protein C with reduced anticoagulant properties while retaining... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20080058256 - Methods for the treatment of thrombosis: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.... Agent: Robins & Pasternak

20080058259 - Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency: The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having insulin-like growth factor-1 deficiency (IGFD). The invention relates to methods comprising administering insulin-like growth factor-I to a patient having a height which, at the time of treatment... Agent: Bozicevic, Field & Francis LLP

20080058266 - Pharmaceutical compositions comprising factor vii polypeptides and factor xi polypeptides: Compositions comprising a factor VII or factor VII-related polypeptide and a factor XI or factor XI-related polypeptide, kits comprising the same, and methods of using such compositions (e.g., in the treatment of bleeding conditions) are provided... Agent: Novo Nordisk, Inc. Patent Department

20080058261 - Protease susceptibility ii: The manipulation of the amino acid sequence of tropoelastin, particularly human tropoelastin, to modify its protease susceptibility is described. The modified tropoelastins include tropoelastin derivatives having modified protease susceptibility, peptidomimetic molecules which contain amino acid sequences which correspond to or incorporate the protease susceptible sequences of tropoelastin. Uses of these... Agent: Howson And Howson

20080058260 - Reversible inhibition of pyramidal gap junction activity: The present invention relates to a novel method of inhibiting gap junction-mediated signaling in pyramid cells. Pyramidal gap junctions are quickly and reversibly inhibited by beta-amyloid or biologically active fragments thereof. The present invention also relates to the use of beta-amyloid as an anticonvulsant for the treatment of epilepsy and... Agent: Kevin Farrell Pierce Atwood

20080058262 - Rpa optimization: An optimized synthetic polynucleotide encoding a Bacillus anthracis protective antigen and an anthrax vaccine based on the encoded protective antigen. Furthermore, heterologous expression in a host Pseudomonas fluorescens bacteria of an optimized polynucleotide sequence encoding a Bacillus anthracis protective antigen.... Agent: Trask Britt

20080058270 - Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.... Agent: Warner-lambert Company

20080058268 - Methods and agents for the treatment of cancer: There are disclosed methods for prophylaxis or treatment of cancer in a mammal. The methods comprise administering an effective amount of an agent to the mammal, which binds to a MAP kinase or an integrin such that binding of the MAP kinase to the integrin is inhibited.... Agent: Edwards Angell Palmer & Dodge LLP

20080058271 - Prevention of primary sjogren' s syndrome by ica69 deficiency: This invention relates to identification of an autoantigen implicated in the development and progression of Sjögren's Syndrome (pSS); particularly to the disease modifying effect of creating a deficiency in the ICA69 autoantigen; and most particularly to development of diagnostic and therapeutic avenues, means for the differential diagnosis of pSS versus... Agent: Mchale & Slavin, P.A.

20080058273 - Compound extracted from husk and fruit stem of xanthoceras sobifolia and its extracting method and use thereof: A method on its extraction: grinding the husk and fruit stem of Xanthoceras Sobifolia into particles, extracting the particles with solvents, filtrating, reclaiming the solvent and collecting the concentrated solution, passing the collection through macroporous resin, eluting it by solvent, reclaiming the solvent to get the enriched solution, drying the... Agent: Smith, Gambrell & Russell

20080058274 - Combination therapy: The present invention concerns a new medical treatment involving the combination of two active entities, as well as pharmaceutical compositions comprising the two active entities. Specifically, the invention provides a pharmaceutical composition comprising a stable lipid assembly comprising as a first active entity an apoptosis-affecting lipid which does not self-aggregate... Agent: Nath & Associates

20080058276 - Alzheimer's disease therapeutics based on pin-1 catalyzed conformational changes in phosphorylated amyloid precursor protein: The present invention is directed to inhibiting amyloidogenic processing of amyloid precursor protein, and/or inhibiting production of amyloid beta peptides. These methods can involve accelerating cis/trans isomerization of amyloid precursor protein at a phosphorylated serine/threonine-proline motif and/or contacting a cell with a compound that mimics the cis conformation of a... Agent: Nixon Peabody LLP - Patent Group

20080058278 - Attenuation of hyperoxia-induced cell death with mitochondrial aldehyde dehydrogenase: Oxygen toxicity is one of the major risk factors in the development of the chronic lung disease or bronchopulmonary dysplasia in premature infants. Using proteomic analysis, we discovered mitochondrial aldehyde dehydrogenase (mtALDH or ALDH2) was down-regulated in neonatal rat lung after hyperoxic exposure. To study the role of mtALDH in... Agent: Erickson & Kleypas, L.L.C.

20080058279 - Ester-linked gemini surfactant compounds for use in gene therapy: This invention relates to newly identified ester-linked Gemini surfactant compounds of formula (I), where Y is either H or (Aa)x where (Aa) is a basic amino acid and x is 1 to 6, to the use of such compounds and to their production. The invention also relates to the use... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080058277 - Methods and compositions for modulating telomerase reverse transcriptase (tert) expression: Methods and compositions are provided for modulating, and generally upregulating, the expression of telomerase reverse transcriptase (TERT) by blocking repression of TERT transcription, e.g., by inhibiting binding of repressor factor to a Site C repressor binding site located in the TERT minimal promoter. The subject methods and compositions find use... Agent: Bozicevic, Field & Francis LLP

20080058280 - Treatment of lymphoma using 10-propargyl-10-deazaaminopterin and gemcitabine: Lymphoma is treated using therapeutic combinations of PDX and gemcitabine by administering to a patient suffering from lymphoma a therapeutically effective amount of PDX in combination with a therapeutically effective amount of gemcitabine. The two agents can be administered together or in either order, although administration of PDX followed by... Agent: Marina Larson & Associates LLC Re: Msk

20080058281 - Skin lightening compositions comprising vitamines and flavonoids: A composition is provided comprising a flavanoid, vitamin C, vitamin E and niacin. The composition can be used as a skin lightening agent.... Agent: Unilever Intellectual Property Group

20080058284 - Pharmaceutical compositions of semicarbazones and/or thiosemicarbazones and/or their derivatives and products of these compositions and their uses as anticonvulsant, anti-nociceptive and anti-inflammatory agents, and in the angiogenic therapy: The present invention is characterized by obtaining inclusion compounds of semicarbazones and/or thiosemicarbazones and/or their derivatives in cyclodextrins and/or their derivatives, which once tested in experimental models of epilepsia allowed the reduction of anticonvulsant dose from 100 mg/kg to 25 mg/kg. This means an increase in bioavailability of compounds in... Agent: Nixon & Vanderhye, PC

20080058285 - Colored perfumed compositions comprising at least one alkyl-beta,beta'-diphenylacrylate or alkyl alpha-cyano-beta,beta'-diphenylacrylate compound and at least one soluble organic uv-a filter: Topically applicable colored and perfumed compositions, well suited for perfuming such human keratinous substrates as the skin, lips and/or integuments, contain, formulated into a cosmetically acceptable medium: a) at least 1% by weight of a perfuming substance; b) at least one volatile alcohol and/or volatile silicone oil; c) at least... Agent: Buchanan, Ingersoll & Rooney PC

20080058286 - Novel applications of omega-3 rich phospholipids: This invention disclose novel uses of omega-3 rich phospholipids for treating diabetes type II, metabolic syndrome, sustained ventricular tachycardia and inflammatory disease. In addition to improving fertility in asthenozoospermic males. The invention also discloses the use of omega-3 rich phospholipids in healthy subject for improving physical endurances, reducing delayed onset... Agent: Casimir Jones, S.c.

20080058287 - Mesotherapy cream: The present disclosure concerns a cream-based composition and method which reduces fat deposits upon topical application to the skin. The active ingredients of the composition include the active ingredients deoxycholic acid and phosphatidyl choline which are mixed together with a cream composition. The active ingredients may be combined with any... Agent: Jennings, Strouss & Salmon, P.L.C

20080058289 - Increasing atp availability by inhibition of creatine kinase (ck) leakage resulting from high-intensity exercise: The present invention relates to a method of increasing Adenosine Triphosphate levels in a mammal wherein 2-(carbamimidoyl-methyl-amino)ethoxyphosphonic acid inhibits the leakage of the Adenosine Triphosphate-dependant enzyme Creatine Kinase. Via the inhibition of Creatine Kinase leakage, Adenosine Triphosphate is not utilized in the conversion of creatine to phosphocreatine, thereby making it... Agent: Torys LLP

20080058288 - Method of increasing intracellular concentrations of phosphate and increasing the force of muscular contractions: The present invention relates to a method of increasing the intracellular concentration of phosphate by employing 2-(carbamimidoyl-methyl-amino)ethoxyphosphonic acid as vehicle and method to transport Phosphate into the cell. The increase in intracellular phosphate increases the availability of Adenosine Triphosphate and phosphocreatine, thereby leading to an increase in the anaerobic energy... Agent: Torys LLP

20080058290 - Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders: Substituted phenol derivatives of Formula (I) are useful as antiproliferative agents including, for example, anticancer agents, and as radioprotective and chemoprotective agents.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080058291 - Insecticidal compositions: This invention relates to topical compositions for treating ectoparasites such as head lice and fleas. The composition comprises an ovicidally effective quantity of salicylic acid (typically 1-10% by weight) dispersed in a liquid vehicle or carrier. The vehicle may be an oily carrier including a mineral oil such as paraffin... Agent: Smith-hill And Bedell, P.C.

20080058292 - Method for increasing hdl and hdl-2b levels: The present invention provides a method for reducing flushing in a patient and for for increasing HDL and/or HDL-2b levels in a patient, with compositions being administered to the patient only twice a day, from 30 to 60 minutes after lunch and 30 to 60 minutes after dinner. In some... Agent: Ronald V. Davidge

20080058293 - Quinoline derivates and their use in therapy: The invention provides compounds of formula (I) wherein n, p, q, X, R1, R2, R3, R4, R5 and R6 are as defined in the specification; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20080058296 - Formulations and methods for treating rhinosinusitis: The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.... Agent: Alston & Bird LLP

20080058294 - Liposomal compositions of glucocorticoid and glucocorticoid derivatives: The present invention provides pharmaceutical compositions comprising a glucocorticoid or glucocorticoid derivative stably encapsulated in a liposome. The glucocorticoid or glucocorticoid derivative is selected from an amphipathic weak base glucocorticoid or glucocorticoid derivative having a pKa equal or below 11 and a logD at pH 7 in the range between... Agent: Nath & Associates

20080058295 - Nasal pharmaceutical formulations and methods of using the same: Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific... Agent: Alston & Bird LLP

20080058297 - Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss: and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, R5, U, V, W, X, Y, Z, and n are defined herein. This invention also relates to compositions comprising these compounds and methods for using them. The compounds and compositions of this invention are useful to... Agent: Edwards Angell Palmer & Dodge LLP

20080058298 - Inhibitors of hedgehog signaling pathways, compositions and uses related thereto: The present invention makes available assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein or aberrant activation of a hedgehog signal transduction pathway, e.g., which involve the use of a steroidal alkaloid or other small molecule.... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080058299 - Method of treating or preventing bone deterioration or osteoporosis: The present invention relates to a transdermal hydroalcoholic testosterone gel formulation and a method for treating, preventing, or reducing the risk of developing deterioration of bone. The present invention also relates to a method for treating, preventing, or reducing the risk of developing osteoporosis.... Agent: Mayer Brown LLP

20080058301 - Formulations: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.... Agent: Hollis-eden Pharmaceuticals, Inc.

20080058300 - Induction of weight loss and the selective inhibition of ptp1b: The present invention is directed to the use of compound 1436 for the induction of weight loss in an obese mammal.... Agent: Morgan Lewis & Bockius LLP

20080058302 - Sulfamoyl benzamides and methods of their use: Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases, ischemic... Agent: Woodcock Washburn LLP

20080058303 - Use of melagatran: According to the invention there is provided the use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, in the manufacture of a medicament for the treatment of inflammation.... Agent: Nixon & Vanderhye, PC

20080058304 - N-hydroxyamide derivatives possessing antibacterial activity: Novel N-hydroxyamide derivatives are disclosed. These N-hydroxyamide derivatives inhibit UPD-3-O—(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase, an enzyme present in gram negative bacteria and are therefore useful as antimicrobials and antibiotics. Methods of synthesis and of use of the compounds are also disclosed.... Agent: Warner-lambert Company

20080058305 - Processes for the purification of (3r,4s)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one: v

20080058306 - Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080058307 - Novel compounds as cannabinoid receptor ligands: e

20080058308 - Novel compounds as cannabinoid receptor ligands:

20080058309 - Novel compounds 171: The invention provides compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy, wherein A, D, R1, R2, R3, R4, R5, R6, n, p and q are as defined in the specification.... Agent: Fish & Richardson P.C.

20080058310 - High-density lipoprotein-cholesterol level elevating agent: A novel high-density lipoprotein(HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory activity.... Agent: Edwards Angell Palmer & Dodge LLP

20080058311 - Novel diarylalkene derivatives and novel diarylalkane derivatives: wherein, A represents CH═CH, etc., a, b, c and d represents CH etc., R1, R2, R3, R4, R5 and R6 represents H etc., V—W represents C═C, etc., n represents 0 to 3, Y1 represents O etc., B represents —(CH2)vCHR21 wherein v is 0 to 3, R21 represents H, a lower... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080058312 - Modulators of hepatocyte growth factor/c-met activity: This invention is directed to compounds and compositions that have biological properties useful for modulating HGF/SF activity. In certain embodiments, said compounds and compositions may be used in the treatment and prophylaxis of cancer or other dysproliferative diseases and inflammatory diseases such as rheumatoid arthritis.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080058313 - Tetrahydro-2h-indazole pyrazole cannabinoid modulators: i

20080058314 - Novel dicarboxylic acid derivatives with pharmaceutical properties:

20080058315 - Integrase inhibitors: Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.... Agent: Gilead Sciences Inc

20080058316 - Cancer treatment with gama-secretase inhibitors: i

20080058318 - Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia: Methods for treating cognitive dysfunction associated with fibromyalgia by administering high-dose milnacipran to a patient suffering from such cognitive dysfunction are provided. Also provided are methods for the long-term treatment of cognitive dysfunction associate with FMS by administering milnacipran to a patient suffering from such cognitive dysfunction.... Agent: Darby & Darby P.C.

20080058317 - Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome: Methods for treating fatigue associated with fibromyalgia by administering high-dose milnacipran to a patient suffering from such fatigue are provided. Also provided are methods for the long-term treatment of fatigue associated with FMS by administering milnacipran to a patient suffering from such fatigue.... Agent: Darby & Darby P.C.

20080058319 - Fused ring heterocycles as potassium channel modulators: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia,... Agent: Townsend And Townsend And Crew, LLP

20080058321 - Benzothiazin-3-one compound and intermediate therefor: (wherein n is 3 or 4; R represents ethyl or hydrogen; and R1 represents hologeno, alkoxy, haloalkyl, or haloalkoxy) or a pharmaceutically acceptable salt thereof. It is useful as a therapeutic or preventive agent for arthrosis deformans, chondrodegenerative discases such as chronic articular rheumatism, cancers, gingivitis, etc. Also provided are... Agent: Sughrue Mion, PLLC

20080058320 - Organic compounds: The invention relates to novel amino alcohols of the general formula (I) where X, R1, R2, R3, R4, R5 and R6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080058323 - Pharmaceutically effective compounds: The subject invention relates to carboxamidine derivatives, to pharmaceutical compositions containing the carboxamidine derivatives of the invention, and the use thereof for the treatment of vascular diseases and in the preparation of pharmaceutical compositions for the treatment of vascular diseases.... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080058322 - Small molecule inhibitors targeted at bcl-2: The present invention relates to small molecule antagonists of Bcl-2 family proteins such as Bcl-2 and/or Bcl-XL. In particular, the present invention provides non-peptide cell permeable small molecules (e.g., tricyclo-dibenzo-diazocine-dioxides) that bind to a pocket in Bcl-2/Bcl-XL that block the anti-apoptotic function of these proteins in cancer cells and tumor... Agent: Casimir Jones, S.c.

20080058324 - Alpha-keto carbonyl calpain inhibitors: The present invention relates to novel a-keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular dystrophies. Disuse atrophy and general muscle wasting can also be treated. Diseases of the eye, in particular cataract, can be treated... Agent: Kilyk & Bowersox, P.l.l.c.

20080058325 - Compounds, methods and pharmaceutical compositions for inhibiting parp: The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”) compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.... Agent: Connolly Bove Lodge & Hutz LLP

20080058326 - Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same: in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted pyrazolopyridine compounds, to methods of preparing said substituted pyrazolopyridines, as well as to uses thereof for manufacturing a pharmaceutical composition for... Agent: Millen, White, Zelano & Branigan, P.C.

20080058327 - Pyrimidyl cyclopentanes as akt protein kinase inhibitors:

20080058329 - Novel indane compounds: The invention provides novel indane compounds which are useful in the treatment of affective disorders, pain disorders, attention deficit hyperactivity disorder (ADHD), cognitive disorders, substance abuse, smoking cessation and stress urinary incontinence.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20080058328 - Substituted 4-phenyltetrahydroisoquinolines, pharmaceuitcal compositions comprising them and therapeutic methods for their use: e

20080058330 - Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof: Provided are compounds which can be used in combination for treating diseases associated with a condition associated with cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau)... Agent: King & Spalding

20080058331 - Inhibitors for glyt-1: o

20080058332 - 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer: The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R1, R2, q, R3, r, R4, X1 and Q1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in... Agent: Morgan Lewis & Bockius LLP

20080058333 - Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors: Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080058334 - Retinoic acid mimetic anilides: the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR3; R1 represents hydrogen, hydroxy, C1-6alkyl or aryl; R2 represents hydrogen; optionally substituted C1-2alkyl; C3-7cycloalkyl; C2-8alkenyl; aryl; Het1; or R1 and R2 taken together may form a bivalent radical of formula... Agent: Philip S. Johnson Johnson & Johnson

20080058335 - Novel compounds as cannabinoid receptor ligands and uses thereof: e

20080058336 - Methods to treat alzheimer's disease:

20080058337 - Pyrrolotriazine kinase inhibitors:

20080058338 - Stable solid dosage forms of aminopterin: There is disclosed stable pharmaceutical compositions containing pharmaceutically acceptable salts of aminopterin surface deposited onto solid excipients. The stable pharmaceutical compositions are hermetically sealed from the atmosphere. The formation of degradation products of aminopterin is reduced or eliminated.... Agent: Syntrix Biosystems, Inc.

20080058339 - New compounds: and pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers and N-oxides thereof. The invention also relates to pharmaceutical compositions comprising these compounds, and to the use of these compounds for the prophylaxis and treatment of medical conditions relating to disorders of the G-protein-coupled receptor GPR119, such as diabetes... Agent: Edwards Angell Palmer & Dodge LLP

20080058340 - Derivatives of n-(arylamino) sulfonamides as inhibitors of mek: This invention concerns N-(2-arylamino) aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20080058341 - Azaindazole compounds and methods of use: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.... Agent: Townsend And Townsend And Crew, LLP

20080058342 - Quinazoline derivatives as angiogenesis inhibitors: The present invention relates to compounds of the Formula (I): wherein: ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which moiety may be saturated or unsaturated, which may be aromatic or non-aromatic, and which optionally may contain 1-3 heteroatoms selected independently from O, N... Agent: Morgan Lewis & Bockius LLP

20080058343 - Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity: or a pharmaceutically acceptable salt, solvate or ester thereof Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080058344 - Enantiomers of 2'-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics: Racemic mixtures and individual enantiomers of fluorine-18 or carbon-11 radio-labelled 2′-alkyl-6-nitroquipazine ligands are serotonin transporter (SERT) tracers for positron emission tomography (PET) imaging. The non-radioactive ligand forms possess therapeutic antidepressant in vitro and in vivo pharmacological binding profiles in rodent brain and cells expressing human serotonin transporter (hSERT). Twelve 2′-alkyl-6-nitroquipazine... Agent: Jean Kyle

20080058345 - Combination therapy with mecamylamine for the treatment of mood disorders: A combination therapy for treating mood disorders, including depressive disorders such as major depression, panic disorder, obsessive compulsive disorder, social anxiety disorder, seasonal affective disorder, and premenstrual dysphoria is provided herein. The combination therapy comprises administering an effettive amount of mecamylamine together with at least one agent for treatment of... Agent: Wolf Greenfield & Sacks, P.C.

20080058346 - Crystalline modifications of n-alpha-(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino- (l)- phenylalanine 4-ethoxycarbonylpiperazide and/or salts thereof: The present invention relates to novel crystalline modifications of N-α-(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanine 4-ethoxycarbonylpiperazide and/or salts thereof, which can be used as pharmaceutical agents, and to pharmaceutical compositions and pharmaceutical uses comprising these novel crystalline modifications.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080058347 - Novel aminopyridine derivatives having aurora a selective inhibitory action: e

20080058348 - Pyrimidine derivatives which are antagonists of vitronectin receptor:

20080058350 - Imidazopyridine and imidazopyrimidine derivatives: The present invention relates to imidazopyridine and imidazopyrimidine derivatives that act as cannabinoid receptor ligands, e.g., CB2 ligands. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20080058349 - New compounds 318: e

20080058351 - Novel heterobicyclic compounds: This invention relates to novel pyrazolo-pyrimidine compounds and their use as analytical tools and in methods of treating neurological disorders, including sleep disorders such as insomnia.... Agent: Edwards Angell Palmer & Dodge LLP

20080058352 - Fungicidal mixtures: in a synergistically effective amount, methods for controlling harmful fungi using mixtures of the compound I with the compound II and the use of the compound I with the compound II for preparing such mixtures, and also compositions comprising these mixtures.... Agent: Birch Stewart Kolasch & Birch

20080058353 - Pharmaceutical compositions: The present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1α, 2α, 3β (1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.... Agent: Pepper Hamilton LLP

20080058354 - Xanthine phosphodiesterase v inhibitors: e

20080058355 - Crystalline erlotinib: Crystalline Forms of erlotinib are made. The crystalline materials are useful as pharmaceutical active agents in treating various cancers as well as in forming erlotinib salts.... Agent: SynthonIPInc

20080058356 - 2,6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists: 4-Aminopyrimidine derivatives of formula (I) FORMULA heteroaryl groups, including pharmaceutically acceptable salts thereof, wherein R1 and R2 are adenosine A2A receptor antagonists useful in the treatment of movement disorders such as Parkinson's disease.... Agent: Seed Intellectual Property Law Group PLLC

20080058359 - Piperidinyl compounds that selectively bind integrins: The invention is directed to piperidinyl compounds that selectively bind integrin receptors and methods for treating an integrin mediated disorder.... Agent: Philip S. Johnson Johnson & Johnson

20080058357 - Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4: Disclosed are compounds, which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a human or animal subject such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease,... Agent: Foley & Lardner LLP

20080058358 - Sulphimides as protein kinase inhibitors: The invention relates to sulphimides as protein kinase inhibitors of the general formula I... Agent: Millen, White, Zelano & Branigan, P.C.

20080058360 - Soluble cd40l (cd 154) as a prognostic marker of atherosclerotic diseases: This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist... Agent: Wolf Greenfield & Sacks, P.C.

20080058361 - Tetrahydrobenzfluorene derivatives: R1 and R2 are independently (1C-4C)alkyl, (2C-4C)alkenyl, hydroxy(2C-4C)alkyl, (1C-3C)alkoxy(2C-4C)alkyl, aryl or aryl(1C-2C)alkyl; or R1 and R2 together with the nitrogen form an aromatic or non-aromatic heterocyclic ring structure, optionally mono- or poly-substituted with (1C-4C)alkyl, (2C-4C)alkenyl, hydroxy(1C-2C)alkyl, (1C-2C)alkoxy(1C-3C)alkyl or aryl. These compounds can be used for estrogen receptor β selective medical... Agent: Organon Usa, Inc. Patent Department

20080058362 - Novel pharmaceutical compositions for treating chronic pain and pain associated with neuropathy: Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a μ-opiate analgesic such as tramadol or an analogously acting molecular... Agent: Nathaniel Gordon-clark

20080058363 - Pharmaceutical composition for treating fecal incontinence and anal itch: Fecal incontinence and anal itch can be treated by administration, more particularly by local application to the anus, of an α adrenergic blocker, nitric oxide synthase inhibitor, prostaglandin F2α, dopamine, morphine, β-blockers, and 5-Hydroxytryptamine. The patients who benefit most from the invention are those who have a normal or low... Agent: Birch Stewart Kolasch & Birch

20080058364 - Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin: The present invention relates to methods of treatment of non-Hodgkin's lymphomas. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxy-camptothecin to patients in need thereof.... Agent: Lucas & Mercanti, LLP

20080058365 - Fused heterocyclic compounds: Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders.... Agent: Jones Day

20080058366 - Rhinitis treatment regimens: A treatment regimen for rhinitis with rhinorrhea includes a daytime dosage unit containing medication for treating rhinitis and an anticholinergic agent for treating rhinorrhea, and a nighttime dosage unit containing medication for treating rhinitis and an attenuated dosage of anticholinergic agent or no anticholinergic agent. A pharmaceutical package for treating... Agent: Mesmer & Deleault, PLLC

20080058367 - Process for the purification of palonosetron or its salt: The present application relates to a process for purification of palonosetron or its salt substantially free of its R-isomer and structure related impurities.... Agent: Dr. Reddy's Laboratories, Inc.

20080058368 - 4,5,6,7-tetrahydro-[1,2]dithiolo[4,3-c] pyridine-3-thione compounds: The present invention relates to new compounds directly increasing kinase activity of p90 ribosomal S6 kinase 1 (RSK1), a pharmaceutical composition comprising them as active ingredient, a use thereof to prevent or treat hepatic fibrosis or cirrhosis, and a method for preventing or treating hepatic fiborsis or cirrhosis, comprising administering... Agent: Birch Stewart Kolasch & Birch

20080058370 - 1-[[1-[(2-amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3h-imidazo[4,5-b]pyridin-3-yl]piperidine and methods of use thereof: and pharmaceutically acceptable salts and solvates thereof. The invention also relates to pharmaceutical compositions comprising the Compound of Formula I and its use in treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease. The invention also relates to the use of a combination of the Compound of... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080058369 - Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors: , or a salt thereof, such as the monohydrochloride salt thereof. The invention also provides the use of the compound or salt as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, or rhinitis... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080058371 - Stabilized difloxacin injectable solution: An antibacterial formulation suitable for injection into animals containing approximately 2-10% w/v difloxacin HCl, L-arginine base, propylene glycol, ethanol and/or benzyl alcohol, and water. The formulation is a solution having a pH of form 9 to 10. The formulation produces little or no tissue damage or irritation at the injection... Agent: Anne M. Rosenblum, Esq

20080058373 - Compositions and methods for treating or preventing glaucoma or progression thereof: A composition for treating or preventing glaucoma or its progression comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It... Agent: Bausch & Lomb Incorporated

20080058372 - Synthesis and antimicrobial activity of novel dicationic ''reversed amidines'': in which R1, R2, R3 and R4 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups; R5 is H, alkyl or aryl; R6 is H, alkyl, aryl, or NR7R8, in which R7 and R8 are each independently selected from the group consisting of... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080058374 - Crystalline forms of a biphenyl compound: The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-[2-({3-[2-(4-hydroxybenzylamino)ethylcarbamoyl]benzoyl}methylamino)ethyl]piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase (Form I or II), a salt such as a hemiedisylate salt or a heminapadisylate salt, or a solvate of a salt such as a heminapadisylate methanolate or a... Agent: Theravance, Inc.

20080058375 - 2-piperidone derivatives as prostaglandin antagonists: wherein m, n, A, X, Y, Z, R1, R2, R4, R6, R7, R8, R9 and R10 are as defined herein, and pharmaceutically acceptable salts, solvates, prodrugs, single isomers or racemic or non-racemic mixture of isomers thereof. The invention also provides methods for preparing, compositions comprising, and methods for using compounds... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080058376 - Piperidines: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides substituted piperidines, and compositions containing these compounds. Also provided are methods using the compounds of the invention for the treatment... Agent: Townsend And Townsend And Crew, LLP

20080058377 - Bicyclic amide, carbamate or urea derivatives as vanilloid receptor modulators: This invention relates to bicyclic amide, carbamate or urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The bicyclic amide, carbamate or urea derivative of the present invention has vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases... Agent: Jeffrey M. Greenman

20080058378 - Compounds which have activity at m1 receptor and their uses in medicine.: wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one or more fluorine atoms; and R6 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080058380 - Acylaminothiazole derivatives, their preparation and their therapeutic use: e

20080058381 - Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity: The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080058379 - Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture: Glucopyranosyl-substituted benzonitrile derivatives as defined herein, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080058382 - Polyamine compounds: This invention relates to methods for treating retinopathy and repairing tissue damage. The methods include administering to a subject in need thereof an effective amount of one or more compounds of the following formula. Each variable in this formula is defined in the specification.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080058383 - Androgen receptor modulators: Treatment of Diseases caused by Disturbances of the Activity of the Androgen Receptor uses of compounds of Formula (I): (as defined herein), for the treatment of diseases caused by disturbances of the activity of androgen receptor are provided: Formula (I). Isolated compounds of Formula (I) are also provided.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20080058384 - Novel compounds: Novel Inhibitors of Rho-kinases are disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080058386 - Indoline-sulfonamides compounds: or R″—C(O)—, and Ar is a substituted or unsubstituted C5-C20 aryl, cyclyl, heterocyclyl, or heteroaryl, R′ and R″ independently is C1-C10 alkyl, or C1-C10 alkoxyl; and R3 is C5-C15 aryl or C1-C10 alkyl. The indoline-sulfonamide compounds disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers... Agent: Bacon & Thomas, PLLC

20080058385 - A crystalline variable hydrate of (s)-6-(4-(2-((3-9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt: The present invention relates to a crystalline variable hydrate of (S)-(3-pyridinecarboxamide,6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl] amino]-2-methylpropyl]phenoxy]-hemi-succinate, a pharmaceutical formulation containing said salt and to methods for treating obesity and/or Type 2 diabetes using said salt.... Agent: Eli Lilly & Company

20080058387 - Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds: e

20080058388 - Treatment of diabetes with thiazolidinedione and sulphonylurea: A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitizer and an insulin secretagogue, to a mammal in need thereof.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080058389 - Carboxamides: The invention relates to novel carboxamides of formula (I), in which M represents a phenyl ring, pyridine ring or pyrimidine, pyridazine or pyrazine ring, respectively monosubstituted by R8, or represents a thiazole ring substituted by R8-A; R8 represents hydrogen, fluorine, chlorine, methyl, isopropyl, methylthio or trifluoromethyl; R8 can also represent... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080058390 - Insecticidal n-substituted (heteroaryl)cycloalkyl sulfoximines: N-Substituted (heteroaryl)cycloalkyl sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20080058391 - Novel compounds: wherein; each of R1 to R4 is independently selected from hydrogen and C1-4 alkyl and each of rings A and B independently is optionally further substituted by up to three substituents, each of which is independently selected from the group consisting of halogen, hydroxy, C1-4alkoxy, C1-4alkyl, C1-5alkanoyl, CF3, CF3O and... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080058392 - Prostaglandin derivatives: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.... Agent: Pfizer Inc

20080058393 - Fungicidal detergent compositions: o

20080058394 - Insecticidal n-substituted (2-substituted-1,3-thiazol)alkyl sulfoximines: N-Substituted (2-substituted-1,3-thiazol)alkyl sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20080058395 - Fused heterocyclic inhibitors of d-amino acid oxidase: S

20080058397 - Therapeutic substituted hydantoins and related compounds:

20080058396 - Methods of stimulating cellular growth, synaptic remodelling and consolidation of long-term memory: The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20080058398 - Compounds: The present invention relates to the tartrate salt of 1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane and solvates thereof, pharmaceutical formulations, processes for their preparation, and their use in medicine.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080058399 - Pharmaceutical compositions: The present invention provides pharmaceutical compositions comprising as an active ingredient candesartan or candesartan cilexetil, compositions exhibiting a relative bioavailability, measured as area under the curve, of more than 1.5.... Agent: Pepper Hamilton LLP

20080058400 - Skin external preparation: A skin external preparation includes at least arginine, aspartic acid, isoleucine, leucine, lysine, threonine, glycine, histidine, serine, valine, tyrosine, cysteine, phenylalanine, hydroxyproline and acylglutamine among amino acids, or salts thereof, and a skin external preparation includes: at least arginine, aspartic acid, isoleucine, leucine, lysine and threonine among amino acids, or... Agent: Birch Stewart Kolasch & Birch

20080058401 - Compounds that inhibit trpv1 and uses thereof: s

20080058402 - Substituted thieno[2,3-c]pyrazoles, process for preparing them, compositions containing them, and use thereof:

20080058403 - Vision through photodynamic therapy of the eye: Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects.... Agent: Morrison & Foerster LLP

20080058404 - Stable pharmaceutical compositions of 2-aza-bicyclo [3.3.0]-octane-3-carboxylic acid derivatives: A stable composition of a 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivative and a method for its preparation are described. The stable composition includes an intimate admixture of the derivative and a stabilizing effective amount of a lubricant. The stable composition further includes an external excipient. A method of preparing the stable composition includes... Agent: Kenyon & Kenyon LLP

20080058405 - Replicating melatonin signaling in a fetus, newborn or suckling infant: A method for achieving a chronobiologic effect on a circadian rhythm in a human infant or fetus in utero is described. The method involves the administration of melatonin or dose-equivalent melatonin analogue or melatonin receptor agonist to an infant by administering melatonin or dose-equivalent melatonin precursor, melatonin analogue or melatonin... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080058406 - Lipoic acid derivatives: The invention describes alpha lipoic acid complexes, that can be oligomeric, polymeric, monomeric and mixtures thereof. The complexes can be salts, chelates, etc. of the oligomers, polymers, or monomeric alpha lipoic acid.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080058408 - Low-dose doxepin for treatment of sleep disorders in elderly patients: Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and... Agent: Knobbe Martens Olson & Bear LLP

20080058407 - Methods of improving the pharmacokinetics of doxepin: Methods of improving the pharmacokinetics of doxepin in a patient.... Agent: Knobbe Martens Olson & Bear LLP

20080058409 - Esterified catechins, processes for producing the same, and foods and beverages as well as cosmetics containing such esterified catechins: The present invention provides substances having sufficiently antibacterial activity against heat-resistant spore-forming bacteria that they can be used to improve the shelf life of beverages and processed foods, as well as to control the growth of microorganisms in cosmetics. The present invention provides a catechin ester in which at least... Agent: Drinker Biddle & Reath (dc)

20080058410 - Composition for stabilizing vitamin c in water phase and method for stabilizing c using thereof: The present invention relates to a composition for stabilizing vitamine C in water phase and method for stabilizing vitamine C using the composition. More particularly, this invention relates to a composition wherein the vitamine C is effectively prevented from decomposing by an exterior environment such as water, temperature, and light... Agent: Marger Johnson & Mccollom, P.C.

20080058411 - Methods for treating resistant or refractory tumors: The instant invention relates to methods, pharmaceutical compositions and packaged pharmaceuticals for treating resistant or refractory tumors by administering platinum-based compounds.... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080058412 - 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same: e

20080058413 - Derivatives of sandalwood oil and santalols for treating cold sores and herpes: wherein SWO refers to collectively the alcohols, including santalol, present in the sandalwood oil; wherein R is selected from alkyl groups of up to about 22 carbon atoms and aryl groups of up to about 22 carbon atoms and alkylene group of up to about 22 carbon atoms and an... Agent: Nathaniel Gordon-clark

20080058414 - Substituted cyclopentanes or cyclopentanones as therapeutic agents: Novel compounds, and therapeutic methods, compositions and medicament related thereto are disclosed herein.... Agent: Allergan, Inc.

20080058415 - Lipid preparation for enhancing mineral absorption: The dietary ingredient is particularly intended for use in enhancing calcium absorption and in the prevention and/or treatment of disorders associated with depletion of bone calcium and bone density, prevention and treatment of osteoporosis, for the enhancement of bone formation and bone mass maximization and for the enhancement of bone... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco

20080058416 - Cns modulators: A method is provided for treating a subject in need of therapy for depression, anxiety, impaired cognition and/or pain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide anti-depressant effect, cognition enhancing and/or analgesic effect. Preferred materials... Agent: Nixon & Vanderhye, PC

20080058417 - Enriched beverages and methods of making the same: The present invention provides a composition that contains a beverage component, pectin and an oil at least one long chain polyunsaturated fatty acid and a method for making the same.... Agent: Sheridan Ross P.C.

20080058418 - Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion: An emulsion comprising a continuous liquid phase, an emulsifier, and a discontinuous liquid phase comprising a blend including a polyunsaturated fatty acid source and a dispersing agent. The polyunsaturated fatty acid source comprises at least one polyunsaturated fatty acid and the weight ratio of the fatty acid source to the... Agent: Sutherland Asbill & Brennan LLP

20080058419 - Treatment of poultry for increasing the feed conversion rate or for reducing the incidence of ascites: The invention relates to a method for the non-therapeutic treatment of poultry for the purpose of reducing the conversion rate of the feed used to raise the poultry. The treatment comprises orally administering at least one glycine compound to the poultry, which glycine compound corresponds to the following formula (I)... Agent: Sughrue Mion, PLLC

20080058420 - Pharmaceutical composition comprising gabapentin: The present invention relates to pharmaceutical compositions comprising gabapentin and a mixture of excipients capable of not promoting the conversion of gabapentin into the corresponding lactamic impurity, processes for their preparation and capsules that contain said compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080058421 - Compositions for cleaning and disinfecting nasal tract and sinus cavity: Biodegradable compositions for cleaning and disinfecting nasal tract and sinus cavity using food additive ingredients or ingredients that are safe.... Agent: Brooks Kushman P.C.

20080058422 - Antineoplastic preparation and the use of antineoplastic preparation: A method for manufacturing an antineoplastic preparation containing alpha-ketoglutarate (AKG) or/and glutamine or/and glutamate or/and alpha-ketoglutarate of ornithine or/and dipeptides of glutamine and other amino acids or/and tripeptides of glutamine and other amino acids or/and di- and tripeptides of glutamate with other amino acid, or/and mono- and divalent metal salts... Agent: Ladas & Parry LLP

20080058423 - Melanin concentrating hormone antagonists: The present invention relates to compounds capable of serving as moderators of human and mammalian appetite and as such provide a means for reducing body mass and controlling obesity.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080058424 - Novel pharmaceutical formulations of modafinil: The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof.... Agent: Cephalon, Inc.

20080058425 - Ethyl nitrite as a gastrointestinal smooth muscle relaxant and diagnostic and therapeutic uses thereof: The present invention provides compositions comprising a gas and a gastrointestinal smooth muscle relaxing agent comprising ethyl nitrite in a therapeutically effective amount. The present invention also provides methods of relaxing gastrointestinal smooth muscle, alleviating contraction or spasm of gastrointestinal smooth muscle to facilitate a diagnostic medical procedure and treating... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080058426 - Composition and method for treating psoriasis: A composition and method for treating psoriasis comprising a mixture of tetrahydrocurcumin, tetrahydrodemethoxycurcumin and tetrahydrobisdemethoxy-curcumin formulated with pharmaceutically acceptable carriers and applied to the affected skin.... Agent: Sabinsa Corporation

20080058427 - Cyclodextrin-based polymers for therapeutics delivery: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080058428 - Method and composition for eliminating odors in ion exchange resins: A method for reducing undesirable odor of an anion exchange resins by preparing a composition comprising an admixture comprising an anion exchange resin having an undesirable odor and a cation exchange resin; and converting the mixture to form the composition.... Agent: Rohm And Haas Company Patent Department

20080058429 - Diagnosis of primary open angle glaucoma: The invention provides methods for diagnosing patients with primary open angle glaucoma (POAG), as well as methods for identifying agents for use in treating POAG and methods of using such agents in prevention and treatment of the disease.... Agent: Clark & Elbing LLP

20080058430 - Method for selecting allosteric regulators of class iii g protein-coupled receptors: The invention relates to a method for identifying and selecting a compound acting as an allosteric regulator of a GPCR-III. According to said method, the activity level of a recombinant GPCR-III (GPCR-III-?), essentially depleted of the extracellular domain of the corresponding native GPCR-III in the presence of a given compound,... Agent: Arent Fox LLP

20080058431 - Modulators of shp2 tyrosine phosphatase and their use in the treatment of body weight disorders: Described are methods and compositions for regulating body weight and/or regulating the rate of weight gain or loss, and particularly, for treating or preventing obesity. Specifically, methods of administering varying levels of Shp2 modulators to an animal, alone or in combination with body weight regulating agents are disclosed. Methods and... Agent: Knobbe Martens Olson & Bear LLP

20080058433 - Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the enzyme peptides, and methods of identifying... Agent: Celera

20080058432 - Molecular assay to predict recurrence of duke's b colon cancer: A method of providing a prognosis of colorectal cancer is conducted by analyzing the expression of a group of genes. Gene expression profiles in a variety of medium such as microarrays are included as are kits that contain them.... Agent: Philip S. Johnson Johnson & Johnson